Jos W M Van Der Meer

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/57572/publications.pdf

Version: 2024-02-01

628 papers	65,248 citations	558 126 h-index	1158 229 g-index
648 all docs	648 docs citations	648 times ranked	58855 citing authors

#	Article	IF	Citations
1	A guide to immunotherapy for COVID-19. Nature Medicine, 2022, 28, 39-50.	30.7	206
2	Reply to: â€˜Lack of evidence for intergenerational inheritance of immune resistance to infectionsâ€™. Nature Immunology, 2022, 23, 208-209.	14.5	9
3	Shifting the Immune Memory Paradigm: Trained Immunity in Viral Infections. Annual Review of Virology, 2022, 9, 469-489.	6.7	9
4	Trained immunity, tolerance, priming and differentiation: distinct immunological processes. Nature Immunology, 2021, 22, 2-6.	14.5	274
5	BCG vaccination in health care providers and the protection against COVID-19. Journal of Clinical Investigation, 2021, 131, .	8.2	30
6	Dysregulated Innate and Adaptive Immune Responses Discriminate Disease Severity in COVID-19. Journal of Infectious Diseases, 2021, 223, 1322-1333.	4.0	61
7	Evolution of cytokine production capacity in ancient and modern European populations. ELife, 2021, 10, .	6.0	15
8	Transmission of trained immunity and heterologous resistance to infections across generations. Nature Immunology, 2021, 22, 1382-1390.	14.5	72
9	Globalization of Traditional Chinese Medicine: what are the issues for ensuring evidenceâ€based diagnosis and therapy?. Journal of Internal Medicine, 2020, 287, 210-213.	6.0	5
10	Safety and COVID-19 Symptoms in Individuals Recently Vaccinated with BCG: a Retrospective Cohort Study. Cell Reports Medicine, 2020, 1, 100073.	6.5	78
11	Multi-omics examination of Q fever fatigue syndrome identifies similarities with chronic fatigue syndrome. Journal of Translational Medicine, 2020, 18, 448.	4.4	21
12	Presence of Genetic Variants Among Young Men With Severe COVID-19. JAMA - Journal of the American Medical Association, 2020, 324, 663.	7.4	626
13	Growth on Carbohydrates from Carbonaceous Meteorites Alters the Immunogenicity of Environment-Derived Bacterial Pathogens. Astrobiology, 2020, 20, 1353-1362.	3.0	3
14	Validity, reliability and feasibility of a new observation rating tool and a post encounter rating tool for the assessment of clinical reasoning skills of medical students during their internal medicine clerkship: a pilot study. BMC Medical Education, 2020, 20, 198.	2.4	4
15	Defining trained immunity and its role in health and disease. Nature Reviews Immunology, 2020, 20, 375-388.	22.7	1,345
16	Immune recognition of putative alien microbial structures: Hostâ€“pathogen interactions in the age of space travel. PLoS Pathogens, 2020, 16, e1008153.	4.7	7
17	Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome. ELife, 2020, 9, .	6.0	235
18	Long-Lasting Transcriptional Changes in Circulating Monocytes of Acute Q Fever Patients. Open Forum Infectious Diseases, 2019, 6, .	0.9	5

#	Article	IF	Citations
19	Mediation analysis shows that a decline in self-efficacy mediates the increase in fatigue severity following an initial positive response to cognitive behavioural therapy in Q fever fatigue syndrome. Journal of Psychosomatic Research, 2019, 127, 109841.	2.6	6
20	Cytokine profiles in patients with Q fever fatigue syndrome. Journal of Infection, 2019, 78, 349-357.	3.3	9
21	A possible role for mitochondrial-derived peptides humanin and MOTS-c in patients with Q fever fatigue syndrome and chronic fatigue syndrome. Journal of Translational Medicine, 2019, 17, 157.	4.4	17
22	A possible link between recurrent upper respiratory tract infections and lower cytokine production in patients with Q fever fatigue syndrome. European Journal of Immunology, 2019, 49, 1015-1022.	2.9	2
23	Long-term effect of cognitive behavioural therapy and doxycycline treatment for patients with Q fever fatigue syndrome: One-year follow-up of the Qure study. Journal of Psychosomatic Research, 2019, 116, 62-67.	2.6	20
24	Systemic Autoinflammatory Syndromes. , 2019, , 825-834.e1.		1
25	Innate immune memory: An evolutionary perspective. Immunological Reviews, 2018, 283, 21-40.	6.0	165
26	Fatigue Is Associated With Altered Monitoring and Preparation of Physical Effort in Patients With Chronic Fatigue Syndrome. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2018, 3, 392-404.	1.5	11
27	Metabolic Induction of Trained Immunity through the Mevalonate Pathway. Cell, 2018, 172, 135-146.e9.	28.9	485
28	Diagnostic yield of FDG-PET/CT in fever of unknown origin: a systematic review, meta-analysis, and Delphi exercise. Clinical Radiology, 2018, 73, 588-589.	1.1	9
29	Effort but not Reward Sensitivity is Altered by Acute Sickness Induced by Experimental Endotoxemia in Humans. Neuropsychopharmacology, 2018, 43, 1107-1118.	5.4	59
30	Long-term prognosis, treatment, and outcome of patients with fever of unknown origin in whom no diagnosis was made despite extensive investigation. Medicine (United States), 2018, 97, e11241.	1.0	20
31	Decontamination of Oral or Digestive Tract for Patients in the Intensive Care Unit. JAMA - Journal of the American Medical Association, 2018, 320, 2081.	7.4	0
32	Hair and salivary cortisol in a cohort of women with chronic fatigue syndrome. Hormones and Behavior, 2018, 103, 1-6.	2.1	19
33	Autoimmunity and B-cell dyscrasia in acute and chronic Q fever: A review of the literature. European Journal of Internal Medicine, 2018, 54, 6-12.	2.2	14
34	Interferon-Î³ and CXCL10 responses related to complaints in patients with Q fever fatigue syndrome. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 1385-1391.	2.9	8
35	High-Mobility Group Nucleosome-Binding Protein 1 as Endogenous Ligand Induces Innate Immune Tolerance in a TLR4-Sirtuin-1 Dependent Manner in Human Blood Peripheral Mononuclear Cells. Frontiers in Immunology, 2018, 9, 526.	4.8	12
36	Metabolome of chronic fatigue syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E910-E910.	7.1	6

#	Article	IF	Citations
37	Trained Immunity: An Ancient Way of Remembering. Cell Host and Microbe, 2017, 21, 297-300.	11.0	196
38	Cytokine Inhibition in Patients With Chronic Fatigue Syndrome. Annals of Internal Medicine, 2017, 166, 557.	3.9	30
39	Reply to Raoult. Clinical Infectious Diseases, 2017, 65, 1055-1056.	5.8	1
40	Effectiveness of Long-term Doxycycline Treatment and Cognitive-Behavioral Therapy on Fatigue Severity in Patients with Q Fever Fatigue Syndrome (Qure Study): A Randomized Controlled Trial. Clinical Infectious Diseases, 2017, 64, 998-1005.	5.8	48
41	Long-term follow-up after cognitive behaviour therapy for chronic fatigue syndrome. Journal of Psychosomatic Research, 2017, 97, 45-51.	2.6	26
42	Intact interferon-Î³ response against Coxiella burnetii by peripheral blood mononuclear cells in chronic Q fever. Clinical Microbiology and Infection, 2017, 23, 209.e9-209.e15.	6.0	20
43	NFKB1 regulates human NK cell maturation and effector functions. Clinical Immunology, 2017, 175, 99-108.	3.2	38
44	Cytokine signature in chronic fatigue syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E9435-E9435.	7.1	1
45	Assessing and regulating homeopathic products. Journal of Internal Medicine, 2017, 282, 563-565.	6.0	5
46	Cytokine Inhibition in Patients With Chronic Fatigue Syndrome. Annals of Internal Medicine, 2017, 167, 448.	3.9	0
47	Hypothesis: stimulation of trained immunity as adjunctive immunotherapy in cancer. Journal of Leukocyte Biology, 2017, 102, 1323-1332.	3.3	35
48	A guiding map for inflammation. Nature Immunology, 2017, 18, 826-831.	14.5	506
49	Risk of infections in patients with gout: a population-based cohort study. Scientific Reports, 2017, 7, 1429.	3.3	18
50	Interleukin-1 as a mediator of fatigue in disease: a narrative review. Journal of Neuroinflammation, 2017, 14, 16.	7.2	60
51	Prefrontal Structure Varies as a Function of Pain Symptoms in Chronic Fatigue Syndrome. Biological Psychiatry, 2017, 81, 358-365.	1.3	25
52	Early and late B-cell developmental impairment in nuclear factor kappa B, subunit 1â€“mutated common variable immunodeficiency disease. Journal of Allergy and Clinical Immunology, 2017, 139, 349-352.e1.	2.9	30
53	Postural orthostatic tachycardia is not a useful diagnostic marker for chronic fatigue syndrome. Journal of Internal Medicine, 2017, 281, 179-188.	6.0	13
54	Familial Autoinflammatory Syndromes. , 2017, , 1666-1684.e4.		2

#	Article	IF	Citations
55	Observable phenomena that reveal medical students' clinical reasoning ability during expert assessment of their history taking: a qualitative study. BMC Medical Education, 2017, 17, 147.	2.4	16
56	Cytokine signatures in chronic fatigue syndrome patients: a Case Control Study and the effect of anakinra treatment. Journal of Translational Medicine, 2017, 15, 267.	4.4	21
57	Can we Tackle the Antibiotic Threat?. European Review, 2016, 24, 49-62.	0.7	2
58	The Role of Dectin-2 for Host Defense Against Disseminated Candidiasis. Journal of Interferon and Cytokine Research, 2016, 36, 267-276.	1.2	45
59	Immunologic defects in severe mucocutaneous HSV-2 infections: Response to IFN-Î³ therapy. Journal of Allergy and Clinical Immunology, 2016, 138, 895-898.	2.9	6
60	Understanding human immune function using the resources from the Human Functional Genomics Project. Nature Medicine, 2016, 22, 831-833.	30.7	63
61	Adaptation and memory in innate immunity. Seminars in Immunology, 2016, 28, 317-318.	5.6	17
62	Glutaminolysis and Fumarate Accumulation Integrate Immunometabolic and Epigenetic Programs in Trained Immunity. Cell Metabolism, 2016, 24, 807-819.	16.2	584
63	The challenge of autoinflammatory syndromes: with an emphasis on hyper-IgD syndrome. Rheumatology, 2016, 55, ii23-ii29.	1.9	12
64	Bartonella quintana lipopolysaccharide (LPS): structure and characteristics of a potent TLR4 antagonist for in-vitro and in-vivo applications. Scientific Reports, 2016, 6, 34221.	3.3	39
65	A Functional Genomics Approach to Understand Variation in Cytokine Production in Humans. Cell, 2016, 167, 1099-1110.e14.	28.9	275
66	Host and Environmental Factors Influencing Individual Human Cytokine Responses. Cell, 2016, 167, 1111-1124.e13.	28.9	364
67	Altered interferon-Î³ response in patients with Q-fever fatigue syndrome. Journal of Infection, 2016, 72, 478-485.	3.3	21
68	Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa. JAMA Dermatology, 2016, 152, 52.	4.1	205
69	Infecties bij patiÃ«nten met een gestoorde afweer. , 2016, , 331-348.		0
70	Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Annals of Internal Medicine, 2015, 163, 885.	3.9	2
71	Cytokine inhibition in chronic fatigue syndrome patients: study protocol for a randomized controlled trial. Trials, 2015, 16, 439.	1.6	7
72	Defective trained immunity in patients with STAT-1-dependent chronic mucocutaneaous candidiasis. Clinical and Experimental Immunology, 2015, 181, 434-440.	2.6	35

#	Article	IF	Citations
73	Central delivery of iodine-125â€“labeled cetuximab, etanercept and anakinra after perispinal injection in rats: possible implications for treating Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2015, 7, 70.	6.2	14
74	Mastâ€cell interleukinâ€1Î², neutrophil interleukinâ€17 and epidermal antimicrobial proteins in the neutrophilic urticarial dermatosis in Schnitzler's syndrome. British Journal of Dermatology, 2015, 173, 448-456.	1.5	35
75	Antiâ€<scp>SSA</scp> antibodies are present in immunoglobulin preparations. Transfusion, 2015, 55, 832-837.	1.6	16
76	Ebola Virus Disease has Features of Hemophagocytic Lymphohistiocytosis Syndrome. Frontiers in Medicine, 2015, 2, 4.	2.6	28
77	The long wait for a breakthrough in chronic fatigue syndrome. BMJ, The, 2015, 350, h2087-h2087.	6.0	11
78	30Âyears hidsâ€”Travels between bedside and bench. Temperature, 2015, 2, 1-7.	3.0	5
79	Genetic Variation in Pattern Recognition Receptors and Adaptor Proteins Associated With Development of Chronic Q Fever. Journal of Infectious Diseases, 2015, 212, 818-829.	4.0	20
80	The Epigenetic Memory of Monocytes and Macrophages as a Novel Drug Target in Atherosclerosis. Clinical Therapeutics, 2015, 37, 914-923.	2.5	52
81	ATP-Induced IL-1ÃŽÂ² Specific Secretion: True Under Stringent Conditions. Frontiers in Immunology, 2015, 6, 54.	4.8	43
82	A comparison of patients with Q fever fatigue syndrome and patients with chronic fatigue syndrome with a focus on inflammatory markers and possible fatigue perpetuating cognitions and behaviour. Journal of Psychosomatic Research, 2015, 79, 295-302.	2.6	24
83	Specific in vitro interferon-gamma and IL-2 production as biomarkers during treatment of chronic Q fever. Frontiers in Microbiology, 2015, 6, 93.	3.5	12
84	Immunotherapy with G-CSF in patients with chronic mucocutaneous candidiasis. Immunology Letters, 2015, 167, 54-56.	2.5	19
85	TLR2/TLR4-dependent exaggerated cytokine production in hyperimmunoglobulinaemia D and periodic fever syndrome. Rheumatology, 2015, 54, 363-368.	1.9	45
86	Protective host defense against disseminated candidiasis is impaired in mice expressing human interleukin-37. Frontiers in Microbiology, 2015, 5, 762.	3.5	21
87	Long-term in vitro and in vivo effects of Î³-irradiated BCG on innate and adaptive immunity. Journal of Leukocyte Biology, 2015, 98, 995-1001.	3.3	74
88	Investigating neural mechanisms of change of cognitive behavioural therapy for chronic fatigue syndrome: a randomized controlled trial. BMC Psychiatry, 2015, 15, 144.	2.6	9
89	Immune defence against Candida fungal infections. Nature Reviews Immunology, 2015, 15, 630-642.	22.7	440
90	Haploinsufficiency of the NF-ÎºB1 Subunit p50 in Common Variable Immunodeficiency. American Journal of Human Genetics, 2015, 97, 389-403.	6.2	232

#	Article	IF	Citations
91	The role of interleukin-1 beta in the pathophysiology of Schnitzlerâ€™s syndrome. Arthritis Research and Therapy, 2015, 17, 187.	3.5	45
92	Trained immunity: A smart way to enhance innate immune defence. Molecular Immunology, 2015, 68, 40-44.	2.2	147
93	Inflammasome-Independent Regulation of IL-1-Family Cytokines. Annual Review of Immunology, 2015, 33, 49-77.	21.8	275
94	Myeloid lineageâ€“restricted somatic mosaicism of NLRP3 mutations in patients with variant Schnitzler syndrome. Journal of Allergy and Clinical Immunology, 2015, 135, 561-564.e4.	2.9	115
95	Compartmentalized Cytokine Responses in Hidradenitis Suppurativa. PLoS ONE, 2015, 10, e0130522.	2.5	57
96	Diagnosis of Coxiella burnetii Infection: Comparison of a Whole Blood Interferon-Gamma Production Assay and a Coxiella ELISPOT. PLoS ONE, 2014, 9, e103749.	2.5	7
97	The discriminative capacity of soluble Toll-like receptor (sTLR)2 and sTLR4 in inflammatory diseases. BMC Immunology, 2014, 15, 55.	2.2	54
98	IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous disease in mice and in humans. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 3526-3531.	7.1	273
99	Tryptophan depletion in chronic fatigue syndrome, a pilot cross-over study. BMC Research Notes, 2014, 7, 650.	1.4	10
100	Long-Lasting Effects of BCG Vaccination on Both Heterologous Th1/Th17 Responses and Innate Trained Immunity. Journal of Innate Immunity, 2014, 6, 152-158.	3.8	478
101	Autophagy Controls BCG-Induced Trained Immunity and the Response to Intravesical BCG Therapy for Bladder Cancer. PLoS Pathogens, 2014, 10, e1004485.	4.7	167
102	Immunochip SNP array identifies novel genetic variants conferring susceptibility to candidaemia. Nature Communications, 2014, 5, 4675.	12.8	76
103	Gene polymorphisms in pattern recognition receptors and susceptibility to idiopathic recurrent vulvovaginal candidiasis. Frontiers in Microbiology, 2014, 5, 483.	3.5	66
104	A combination of interferon-gamma and interleukin-2 production by Coxiella burnetii-stimulated circulating cells discriminates between chronic Q fever and past Q fever. Clinical Microbiology and Infection, 2014, 20, 642-650.	6.0	32
105	Comment on â€œPower of Rare Diseases: Found in Translationâ€. Science Translational Medicine, 2014, 6, 219le1.	12.4	3
106	Trained Immunity or Tolerance: Opposing Functional Programs Induced in Human Monocytes after Engagement of Various Pattern Recognition Receptors. Vaccine Journal, 2014, 21, 534-545.	3.1	262
107	Inflammatory responses to infection: The Dutch contribution. Immunology Letters, 2014, 162, 113-120.	2.5	1
108	Cytokine Production Assays Reveal Discriminatory Immune Defects in Adults with Recurrent Infections and Noninfectious Inflammation. Vaccine Journal, 2014, 21, 1061-1069.	3.1	5

#	Article	IF	Citations
109	Role of Dectin-2 for Host Defense against Systemic Infection with Candida glabrata. Infection and Immunity, 2014, 82, 1064-1073.	2.2	100
110	Immunogenicity of the Q fever skin test. Journal of Infection, 2014, 69, 161-164.	3.3	7
111	Skin Microbiome Imbalance in Patients with STAT1/STAT3 Defects Impairs Innate Host Defense Responses. Journal of Innate Immunity, 2014, 6, 253-262.	3.8	83
112	Mevalonate kinase deficiency nomenclature. Rheumatology International, 2014, 34, 295-296.	3.0	2
113	Innate immune memory: towards a better understanding of host defense mechanisms. Current Opinion in Immunology, 2014, 29, 1-7.	5.5	214
114	Convergent evolution in European and Rroma populations reveals pressure exerted by plague on Toll-like receptors. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 2668-2673.	7.1	88
115	BCG-induced trained immunity in NK cells: Role for non-specific protection to infection. Clinical Immunology, 2014, 155, 213-219.	3.2	359
116	Antimicrobial innovation: combining commitment, creativity and coherence. Nature Reviews Drug Discovery, 2014, 13, 709-710.	46.4	13
117	Human TLR10 is an anti-inflammatory pattern-recognition receptor. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E4478-84.	7.1	211
118	Innate immunity networks during infection withBorrelia burgdorferi. Critical Reviews in Microbiology, 2014, 42, 1-12.	6.1	42
119	Role of autophagy genetic variants for the risk of Candida infections. Medical Mycology, 2014, 52, 333-341.	0.7	17
120	MEFVmutations affecting pyrin amino acid 577 cause autosomal dominant autoinflammatory disease. Annals of the Rheumatic Diseases, 2014, 73, 455-461.	0.9	101
121	Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity. Science, 2014, 345, 1251086.	12.6	1,338
122	Carbon: No silver bullet. Science, 2014, 345, 1130-1130.	12.6	12
123	Differential role of NK cells against Candida albicans infection in immunocompetent or immunocompromised mice. European Journal of Immunology, 2014, 44, 2405-2414.	2.9	41
124	Student performance of the general physical examination in internal medicine: an observational study. BMC Medical Education, 2014, 14, 73.	2.4	38
125	mTOR- and HIF-1Î±â€“mediated aerobic glycolysis as metabolic basis for trained immunity. Science, 2014, 345, 1250684.	12.6	1,517
126	Oxidized Low-Density Lipoprotein Induces Long-Term Proinflammatory Cytokine Production and Foam Cell Formation via Epigenetic Reprogramming of Monocytes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1731-1738.	2.4	486

#	Article	IF	Citations
127	The Qure study: Q fever fatigue syndrome â€“ response to treatment; a randomized placebo-controlled trial. BMC Infectious Diseases, 2013, 13, 157.	2.9	22
128	A Salty Taste to Autoimmunity. New England Journal of Medicine, 2013, 368, 2520-2521.	27.0	57
129	Selective digestive decontamination and bacterial resistance â€“ Authors' reply. Lancet Infectious Diseases, The, 2013, 13, 738-739.	9.1	0
130	Limited humoral and cellular responses to QÂfever vaccination in older adults with risk factors for chronic Q fever. Journal of Infection, 2013, 67, 565-573.	3.3	27
131	Treating inflammation by blocking interleukin-1 in humans. Seminars in Immunology, 2013, 25, 469-484.	5.6	471
132	A novel splice variant of FcÎ³RIIa: AÂrisk factor for anaphylaxis in patients with hypogammaglobulinemia. Journal of Allergy and Clinical Immunology, 2013, 131, 1408-1416.e5.	2.9	43
133	Functional genomics identifies type I interferon pathway as central for host defense against Candida albicans. Nature Communications, 2013, 4, 1342.	12.8	157
134	Resistance to selective decontamination: the jury is still out. Lancet Infectious Diseases, The, 2013, 13, 282-283.	9.1	15
135	Bacterial translocation in an experimental model of multiple organ dysfunctions. Journal of Surgical Research, 2013, 183, 686-694.	1.6	20
136	TREM-1: intracellular signaling pathways and interaction with pattern recognition receptors. Journal of Leukocyte Biology, 2013, 93, 209-215.	3.3	215
137	The <scp>IL</scp>â€36 receptor pathway regulates <scp>A</scp>spergillus fumigatusâ€induced <scp>T</scp>h1 and <scp>T</scp>h17 responses. European Journal of Immunology, 2013, 43, 416-426.	2.9	93
138	Towards a role of interleukin-32 in atherosclerosis. Cytokine, 2013, 64, 433-440.	3.2	39
139	A core physical examination in internal medicine: What should students do and how about their supervisors?. Medical Teacher, 2013, 35, e1472-e1477.	1.8	20
140	Aspergillus fumigatusâ€“Induced IL-22 Is Not Restricted to a Specific Th Cell Subset and Is Dependent on Complement Receptor 3. Journal of Immunology, 2013, 190, 5629-5639.	0.8	38
141	Trained innate immunity and atherosclerosis. Current Opinion in Lipidology, 2013, 24, 487-492.	2.7	51
142	Candida albicans Primes TLR Cytokine Responses through a Dectin-1/Raf-1â€“Mediated Pathway. Journal of Immunology, 2013, 190, 4129-4135.	0.8	57
143	Role of NOD1 polymorphism in susceptibility and clinical progression of rheumatoid arthritis. Rheumatology, 2013, 52, 806-814.	1.9	13
144	Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome. Annals of the Rheumatic Diseases, 2013, 72, 1634-1638.	0.9	90

#	Article	IF	Citations
145	Autophagy Modulates Borrelia burgdorferi-induced Production of Interleukin-1Î² (IL-1Î²). Journal of Biological Chemistry, 2013, 288, 8658-8666.	3.4	21
146	Specific Interferon Î³ Detection for the Diagnosis of Previous Q Fever. Clinical Infectious Diseases, 2013, 56, 1742-1751.	5.8	38
147	The infectious disease challenges of our time. Frontiers in Public Health, 2013, 1, 7.	2.7	14
148	Deficient Candida-Specific T-Helper 17 Response During Sepsis. Journal of Infectious Diseases, 2012, 206, 1798-1802.	4.0	15
149	Effect of Clarithromycin in Inflammatory Markers of Patients with Ventilator-Associated Pneumonia and Sepsis Caused by Gram-Negative Bacteria: Results from a Randomized Clinical Study. Antimicrobial Agents and Chemotherapy, 2012, 56, 3819-3825.	3.2	57
150	IL-18 Serum Concentration Is Markedly Elevated in Acute EBV Infection and Can Serve as a Marker for Disease Severity. Journal of Infectious Diseases, 2012, 206, 197-201.	4.0	51
151	Mast Cells Induce Vascular Smooth Muscle Cell Apoptosis via a Toll-Like Receptor 4 Activation Pathway. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 1960-1969.	2.4	48
152	Different Patterns of Toll-Like Receptor 2 Polymorphisms in Populations of Various Ethnic and Geographic Origins. Infection and Immunity, 2012, 80, 1917-1922.	2.2	36
153	Neutrophil-Mediated Inhibition of Proinflammatory Cytokine Responses. Journal of Immunology, 2012, 189, 4806-4815.	0.8	61
154	IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 3001-3005.	7.1	308
155	High variability of TLR4 gene in different ethnic groups in Iran. Innate Immunity, 2012, 18, 492-502.	2.4	12
156	Vermeer and Leeuwenhoek, Figments of the Imagination?. FASEB Journal, 2012, 26, 2238-2238.	0.5	0
157	Toll-like Receptor 1 Polymorphisms Increase Susceptibility to Candidemia. Journal of Infectious Diseases, 2012, 205, 934-943.	4.0	116
158	Cytokine Gene Polymorphisms and the Outcome of Invasive Candidiasis: A Prospective Cohort Study. Clinical Infectious Diseases, 2012, 54, 502-510.	5.8	68
159	XMRV and CFSâ€"the sad end of a story. Lancet, The, 2012, 379, e27-e28.	13.7	16
160	Primary immunodeficiencies of pattern recognition receptors. Journal of Internal Medicine, 2012, 272, 517-527.	6.0	14
161	Resistance after selective decontamination. Lancet Infectious Diseases, The, 2012, 12, 179.	9.1	0
162	Candida albicans Infection Affords Protection against Reinfection via Functional Reprogramming of Monocytes. Cell Host and Microbe, 2012, 12, 223-232.	11.0	926

#	Article	IF	Citations
163	Association of esophageal candidiasis and squamous cell carcinoma. Medical Mycology Case Reports, 2012, 1, 5-8.	1.3	45
164	Bacille Calmette-GuÃ©rin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 17537-17542.	7.1	1,294
165	Modulation of inflammation by autophagy: consequences for Crohn's disease. Current Opinion in Pharmacology, 2012, 12, 497-502.	3.5	28
166	Association of Mal/TIRAP S180L variant polymorphism with decreased infection risk in patients with advanced HIV-1 infection. Cytokine, 2012, 60, 104-107.	3.2	5
167	The Evolutionary History of TLR4 Polymorphisms in Europe. Journal of Innate Immunity, 2012, 4, 168-175.	3.8	19
168	Murine Borrelia arthritis is highly dependent on ASC and caspase-1, but independent of NLRP3. Arthritis Research and Therapy, 2012, 14, R247.	3.5	20
169	Enhanced interleukin-1Î² production of PBMCs from patients with gout after stimulation with Toll-like receptor-2 ligands and urate crystals. Arthritis Research and Therapy, 2012, 14, R158.	3.5	70
170	Y-Chromosome Analysis in Individuals Bearing the Basarab Name of the First Dynasty of Wallachian Kings. PLoS ONE, 2012, 7, e41803.	2.5	11
171	Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nature Reviews Drug Discovery, 2012, 11, 633-652.	46.4	1,479
172	Complement plays a central role in <scp>C</scp>andida albicansâ€induced cytokine production by human <scp>PBMC</scp>s. European Journal of Immunology, 2012, 42, 993-1004.	2.9	57
173	Low prevalence of lactase persistence in Neolithic South-West Europe. European Journal of Human Genetics, 2012, 20, 778-782.	2.8	55
174	Human genetic susceptibility toCandidainfections. Medical Mycology, 2012, 50, 785-794.	0.7	37
175	A controversial consensus â€“ comment on article by Broderick et al. Journal of Internal Medicine, 2012, 271, 29-31.	6.0	12
176	The Loss of Functional Caspase-12 in Europe Is a Pre-Neolithic Event. PLoS ONE, 2012, 7, e37022.	2.5	10
177	Required Actions to Control Antimicrobial Resistant Healthcare-Associated Infections. , 2012, , 183-202.		0
178	Inhibition of caspase-1 activation in gram-negative sepsis and experimental endotoxemia. Critical Care, 2011, 15, R27.	5.8	61
179	Crohn's disease-associated ATG16L1 polymorphism modulates pro-inflammatory cytokine responses selectively upon activation of NOD2. Gut, 2011, 60, 1229-1235.	12.1	172
180	Successful canakinumab treatment identifies IL-1Î² as a pivotal mediator in Schnitzler syndrome. Journal of Allergy and Clinical Immunology, 2011, 128, 1352-1354.	2.9	49

#	Article	IF	Citations
181	Immunodeficiency and Genetic Defects of Pattern-Recognition Receptors. New England Journal of Medicine, 2011, 364, 60-70.	27.0	89
182	STAT1Mutations in Autosomal Dominant Chronic Mucocutaneous Candidiasis. New England Journal of Medicine, 2011, 365, 54-61.	27.0	614
183	Variable expression and treatment of PAPA syndrome. Annals of the Rheumatic Diseases, 2011, 70, 1168-1170.	0.9	42
184	Trained Immunity: A Memory for Innate Host Defense. Cell Host and Microbe, 2011, 9, 355-361.	11.0	1,177
185	Defects of pattern recognition: primary immunodeficiencies of the innate immune system. Current Opinion in Pharmacology, 2011, 11, 412-422.	3.5	7
186	PS2-102. Cross-tolerance and priming between C-type lectin receptors and TLRs. Cytokine, 2011, 56, 92-93.	3.2	0
187	Society's failure to protect a precious resource: antibiotics. Lancet, The, 2011, 378, 369-371.	13.7	259
188	Effects of the Histone Deacetylase Inhibitor ITF2357 in Autoinflammatory Syndromes. Molecular Medicine, 2011, 17, 363-368.	4.4	23
189	Inflammasome-Independent Modulation of Cytokine Response by Autophagy in Human Cells. PLoS ONE, 2011, 6, e18666.	2.5	182
190	STAT1 Hyperphosphorylation and Defective IL12R/IL23R Signaling Underlie Defective Immunity in Autosomal Dominant Chronic Mucocutaneous Candidiasis. PLoS ONE, 2011, 6, e29248.	2.5	101
191	TREM-1 interaction with the LPS/TLR4 receptor complex. European Cytokine Network, 2011, 22, 11-14.	2.0	54
192	Efficacy and safety of a nanofiltered liquid intravenous immunoglobulin product in patients with primary immunodeficiency and idiopathic thrombocytopenic purpura. Vox Sanguinis, 2011, 101, 138-146.	1.5	18
193	Autophagy modulates the Mycobacterium tuberculosis-induced cytokine response. Immunology, 2011, 134, 341-348.	4.4	73
194	Genetic Variation in the Dectin-1/CARD9 Recognition Pathway and Susceptibility to Candidemia. Journal of Infectious Diseases, 2011, 204, 1138-1145.	4.0	80
195	Borrelia species induce inflammasome activation and ILâ€1â€17 production through a caspaseâ€1â€dependent mechanism. European Journal of Immunology, 2011, 41, 172-181.	2.9	37
196	The inflammasome drives protective Th1 and Th17 cellular responses in disseminated candidiasis. European Journal of Immunology, 2011, 41, 2260-2268.	2.9	126
197	The classical CD14⁺⁺CD16^{â^'} monocytes, but not the patrolling CD14⁺CD16⁺ monocytes, promote Th17 responses to Candida albicans. European Journal of Immunology, 2011, 41, 2915-2924.	2.9	45
198	The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis and Rheumatism, 2011, 63, 1507-1516.	6.7	154

#	Article	IF	Citations
199	Aspergillus fumigatus cell wall components differentially modulate host TLR2 and TLR4 responses. Microbes and Infection, 2011, 13, 151-159.	1.9	93
200	The Changing Burden of Infectious Disease in Europe. Science Translational Medicine, 2011, 3, 103cm30.	12.4	15
201	Neisseria meningitidis lipid A mutant LPSs function as LPS antagonists in humans by inhibiting TLR 4-dependent cytokine production. Innate Immunity, 2011, 17, 517-525.	2.4	14
202	The dectin-1/inflammasome pathway is responsible for the induction of protective T-helper 17 responses that discriminate between yeasts and hyphae ofCandida albicans. Journal of Leukocyte Biology, 2011, 90, 357-366.	3.3	169
203	Role of Interleukin-23 (IL-23) Receptor Signaling for IL-17 Responses in Human Lyme Disease. Infection and Immunity, 2011, 79, 4681-4687.	2.2	34
204	How should we define health?. BMJ: British Medical Journal, 2011, 343, d4163-d4163.	2.3	1,632
205	On-demand anakinra treatment is effective in mevalonate kinase deficiency. Annals of the Rheumatic Diseases, 2011, 70, 2155-2158.	0.9	142
206	Variation in Genes of Î²-glucan Recognition Pathway and Susceptibility to Opportunistic Infections in HIV-Positive Patients. Immunological Investigations, 2011, 40, 735-750.	2.0	7
207	TLR1/TLR2 Heterodimers Play an Important Role in the Recognition of Borrelia Spirochetes. PLoS ONE, 2011, 6, e25998.	2.5	57
208	Anakinra for the inflammatory complications of chronic granulomatous disease. Netherlands Journal of Medicine, 2011, 69, 95.	0.5	18
209	DIFFERENTIAL EFFECTS OF IL-17 PATHWAY IN DISSEMINATED CANDIDIASIS AND ZYMOSAN-INDUCED MULTIPLE ORGAN FAILURE. Shock, 2010, 34, 407-411.	2.1	36
210	Prevalence of xenotropic murine leukaemia virus-related virus in patients with chronic fatigue syndrome in the Netherlands: retrospective analysis of samples from an established cohort. BMJ: British Medical Journal, 2010, 340, c1018-c1018.	2.3	143
211	Zinc and vitamin A supplementation fails to reduce sputum conversion time in severely malnourished pulmonary tuberculosis patients in Indonesia. Nutrition Journal, 2010, 9, 41.	3.4	47
212	Engagement of fatty acids with tollâ€like receptor 2 drives interleukinâ€1Î² production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystalâ€“induced gouty arthritis. Arthritis and Rheumatism, 2010, 62, 3237-3248.	6.7	259
213	Novel strategies for the prevention and treatment ofCandidainfections: the potential of immunotherapy. FEMS Microbiology Reviews, 2010, 34, 1063-1075.	8.6	38
214	Differential susceptibility to lethal endotoxaemia in mice deficient in ILâ€1Î±, ILâ€1Î² or ILâ€1 receptor type I. Apmis, 2010, 118, 1000-1007.	2.0	24
215	Maternal micronutrient supplementation with zinc and Î²-carotene affects morbidity and immune function of infants during the first 6 months of life. European Journal of Clinical Nutrition, 2010, 64, 1072-1079.	2.9	48
216	Milder clinical hyperimmunoglobulin E syndrome phenotype is associated with partial interleukin-17 deficiency. Clinical and Experimental Immunology, 2010, 159, 57-64.	2.6	31

#	Article	IF	Citations
217	IL-1 family nomenclature. Nature Immunology, 2010, 11, 973-973.	14.5	294
218	Recognition ofBorrelia burgdorferiby NOD2 Is Central for the Induction of an Inflammatory Reaction. Journal of Infectious Diseases, 2010, 201, 1849-1858.	4.0	64
219	Candida albicans Releases Soluble Factors That Potentiate Cytokine Production by Human Cells through a Protease-Activated Receptor 1- and 2-Independent Pathway. Infection and Immunity, 2010, 78, 393-399.	2.2	19
220	Mycobacterium tuberculosis induces IL-17A responses through TLR4 and dectin-1 and is critically dependent on endogenous IL-1. Journal of Leukocyte Biology, 2010, 88, 227-232.	3.3	97
221	Association of Tollâ€Like Receptor 4 Asp299Gly and Thr399Ile Polymorphisms with Increased Infection Risk in Patients with Advanced HIVâ€1 Infection. Clinical Infectious Diseases, 2010, 51, 242-247.	5.8	29
222	Translational Medicine Policy Issues in Infectious Disease. Science Translational Medicine, 2010, 2, 14cm2.	12.4	6
223	Blocking IL-1Î² to slow down progression of ALS?. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 12741-12742.	7.1	11
224	Candida albicans Dampens Host Defense by Downregulating IL-17 Production. Journal of Immunology, 2010, 185, 2450-2457.	0.8	78
225	The Candida Th17 response is dependent on mannan- and Â-glucan-induced prostaglandin E2. International Immunology, 2010, 22, 889-895.	4.0	73
226	IL-1Î² Processing in Host Defense: Beyond the Inflammasomes. PLoS Pathogens, 2010, 6, e1000661.	4.7	427
227	Possible Detrimental Effects of Cognitive Behaviour Therapy for Chronic Fatigue Syndrome. Psychotherapy and Psychosomatics, 2010, 79, 249-256.	8.8	46
228	Comment on â€œDetection of an Infectious Retrovirus, XMRV, in Blood Cells of Patients with Chronic Fatigue Syndromeâ€• Science, 2010, 328, 825-825.	12.6	11
229	Severe Candida spp. infections: new insights into natural immunity. International Journal of Antimicrobial Agents, 2010, 36, S58-S62.	2.5	57
230	Influence of genetic variations in TLR4 and TIRAP/Mal on the course of sepsis and pneumonia and cytokine release: an observational study in three cohorts. Critical Care, 2010, 14, R103.	5.8	72
231	Antibiotic use: How to improve it?. International Journal of Medical Microbiology, 2010, 300, 351-356.	3.6	77
232	The Inflammasome-Mediated Caspase-1 Activation Controls Adipocyte Differentiation and Insulin Sensitivity. Cell Metabolism, 2010, 12, 593-605.	16.2	558
233	The role of Toll-like receptors and C-type lectins for vaccination against Candida albicans. Vaccine, 2010, 28, 614-622.	3.8	40
234	Barriers to implementing infection prevention and control guidelines during crises: Experiences of health care professionals. American Journal of Infection Control, 2010, 38, 726-733.	2.3	23

#	Article	IF	Citations
235	Reactive oxygen speciesâ€“independent activation of the IL-1Î² inflammasome in cells from patients with chronic granulomatous disease. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 3030-3033.	7.1	226
236	Antibiotic prescribing in hospitals: a social and behavioural scientific approach. Lancet Infectious Diseases, The, 2010, 10, 167-175.	9.1	265
237	Variable recognition ofCandida albicansstrains by TLR4 and lectin recognition receptors. Medical Mycology, 2010, 48, 897-903.	0.7	64
238	The Effect of Ondansetron, a 5-HT3Receptor Antagonist, in Chronic Fatigue Syndrome. Journal of Clinical Psychiatry, 2010, 71, 528-533.	2.2	12
239	Chronic yersiniosis due to defects in the TLR5 and NOD2 recognition pathways. Netherlands Journal of Medicine, 2010, 68, 310-5.	0.5	14
240	Persistence of full-length caspase-12 and its relation to malaria in West and Central African populations. European Cytokine Network, 2010, 21, 77-83.	2.0	9
241	Influence of innate cytokine production capacity on clinical manifestation and severity of pediatric meningococcal disease. Critical Care Medicine, 2009, 37, 2812-2818.	0.9	2
242	Circulating Leptin and Adiponectin Concentrations During Tumor Necrosis Factor Blockade in Patients with Active Rheumatoid Arthritis. Journal of Rheumatology, 2009, 36, 724-730.	2.0	68
243	Functional and genetic evidence that the Mal/TIRAP allele variant 180L has been selected by providing protection against septic shock. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 10272-10277.	7.1	87
244	Letter to the Editor: Chronic fatigue in Gulf War veterans: should it be treated as chronic fatigue syndrome?. Psychological Medicine, 2009, 39, 1401-1402.	4.5	0
245	Letter to the Editor: The experience of fatigue in the brain. Psychological Medicine, 2009, 39, 523-524.	4.5	3
246	Reply: Change in grey matter volume cannot be assumed to be due to cognitive behavioural therapy. Brain, 2009, 132, e120-e120.	7.6	0
247	Reply to: can CBT substantially change grey matter volume in chronic fatigue syndrome?. Brain, 2009, 132, e111-e111.	7.6	0
248	Antibiotic stewardship and consumption: findings from a pan-European hospital study. Journal of Antimicrobial Chemotherapy, 2009, 64, 853-860.	3.0	44
249	Modulation of Toll-Like Receptor 2 (TLR2) and TLR4 Responses byAspergillus fumigatus. Infection and Immunity, 2009, 77, 2184-2192.	2.2	100
250	Mannoseâ€Binding Lectin Is a Critical Factor in Systemic Complement Activation during Meningococcal Septic Shock. Clinical Infectious Diseases, 2009, 49, 1380-1386.	5.8	22
251	Receptor Recognition of and Immune Intracellular Pathways for Veillonella parvula Lipopolysaccharide. Vaccine Journal, 2009, 16, 1804-1809.	3.1	50
252	Bypassing Pathogenâ€Induced Inflammasome Activation for the Regulation of Interleukinâ€1Î² Production by the Fungal PathogenCandida albicans. Journal of Infectious Diseases, 2009, 199, 1087-1096.	4.0	70

#	Article	IF	Citations
253	Transcriptional and inflammasomeâ€mediated pathways for the induction of ILâ€1Î² production by Mycobacterium tuberculosis. European Journal of Immunology, 2009, 39, 1914-1922.	2.9	75
254	Inflammatory arthritis in caspase 1 geneâ€“deficient mice: Contribution of proteinase 3 to caspase 1â€“independent production of bioactive interleukinâ€1Î². Arthritis and Rheumatism, 2009, 60, 3651-3662.	6.7	274
255	Dysregulation of innate immunity: hereditary periodic fever syndromes. British Journal of Haematology, 2009, 144, 279-302.	2.5	37
256	Serum bactericidal activity against Helicobacter pylori in patients with hypogammaglobulinaemia. Clinical and Experimental Immunology, 2009, 156, 434-439.	2.6	22
257	Cathepsin D activity protects against development of type AA amyloid fibrils. European Journal of Clinical Investigation, 2009, 39, 412-416.	3.4	16
258	Vitamin A deficiency and other factors associated with severe tuberculosis in Timor and Rote Islands, East Nusa Tenggara Province, Indonesia. European Journal of Clinical Nutrition, 2009, 63, 1130-1135.	2.9	25
259	Polymorphism in innate immunity genes and susceptibility to recurrent vulvovaginal candidiasis. Journal De Mycologie Medicale, 2009, 19, 191-196.	1.5	6
260	Crystals of monosodium urate monohydrate enhance lipopolysaccharide-induced release of interleukin 1Î² by mononuclear cells through a caspase 1-mediated process. Annals of the Rheumatic Diseases, 2009, 68, 273-278.	0.9	111
261	Caspase-1, but not ASC or NLRP3 inflammasome components, mediates IL-1beta activation and antifungal defense in disseminated candidiasis. Cytokine, 2009, 48, 120.	3.2	0
262	The Macrophage Mannose Receptor Induces IL-17 in Response to Candida albicans. Cell Host and Microbe, 2009, 5, 329-340.	11.0	294
263	Human Dectin-1 Deficiency and Mucocutaneous Fungal Infections. New England Journal of Medicine, 2009, 361, 1760-1767.	27.0	671
264	Differential requirement for the activation of the inflammasome for processing and release of IL-1Î² in monocytes and macrophages. Blood, 2009, 113, 2324-2335.	1.4	714
265	PENTRAXIN 3 AND C-REACTIVE PROTEIN IN SEVERE MENINGOCOCCAL DISEASE. Shock, 2009, 31, 28-32.	2.1	83
266	Influence of innate cytokine production capacity on clinical manifestation and severity of pediatric meningococcal disease. Critical Care Medicine, 2009, 37, 2812-2818.	0.9	8
267	Cytokine production from stimulated whole blood cultures inÂrheumatoid arthritis patients treated withÂvarious TNF blocking agents. European Cytokine Network, 2009, 20, 88-93.	2.0	16
268	Circulating Lipoproteins Are a Crucial Component of Host Defense against Invasive Salmonella typhimurium Infection. PLoS ONE, 2009, 4, e4237.	2.5	23
269	Caspase-12 and the Inflammatory Response to Yersinia pestis. PLoS ONE, 2009, 4, e6870.	2.5	26
270	Th17 responses and host defense against microorganisms: an overview. BMB Reports, 2009, 42, 776-787.	2.4	91

#	Article	IF	Citations
271	The role of interferon-gamma in the increased tuberculosis risk in type 2 diabetes mellitus. European Journal of Clinical Microbiology and Infectious Diseases, 2008, 27, 97-103.	2.9	111
272	Engagement of NOD2 has a dual effect on proILâ€1Î² mRNA transcription and secretion of bioactive ILâ€1Î². European Journal of Immunology, 2008, 38, 184-191.	2.9	69
273	Role of TLR1 and TLR6 in the host defense against disseminated candidiasis. FEMS Immunology and Medical Microbiology, 2008, 52, 118-123.	2.7	87
274	Interleukin-18 resistance in patients with obesity and type 2 diabetes mellitus. International Journal of Obesity, 2008, 32, 1407-1414.	3.4	56
275	Concentration-dependency of Î²-lactam-induced filament formation in Gram-negative bacteria. Clinical Microbiology and Infection, 2008, 14, 344-349.	6.0	51
276	Crohnâ€™s disease patients homozygous for the 3020insC NOD2 mutation have a defective NOD2/TLR4 crossâ€tolerance to intestinal stimuli. Immunology, 2008, 123, 600-605.	4.4	53
277	Response to â€œSchnitzler's Syndrome: A True Auto-Inflammatory Disorder?â€• Seminars in Arthritis and Rheumatism, 2008, 38, 164.	3.4	0
278	The role of NLRs and TLRs in the activation of the inflammasome. Expert Opinion on Biological Therapy, 2008, 8, 1867-1872.	3.1	57
279	Hostâ€“microbe interactions: innate pattern recognition of fungal pathogens. Current Opinion in Microbiology, 2008, 11, 305-312.	5.1	140
280	Redundant role of TLR9 for anti-Candida host defense. Immunobiology, 2008, 213, 613-620.	1.9	46
281	Î±⁺â€Thalassemia Protects against Anemia Associated with Asymptomatic Malaria: Evidence from Communityâ€Based Surveys in Tanzania and Kenya. Journal of Infectious Diseases, 2008, 198, 401-408.	4.0	32
282	Drosomycin-Like Defensin, a Human Homologue ofDrosophila melanogasterDrosomycin with Antifungal Activity. Antimicrobial Agents and Chemotherapy, 2008, 52, 1407-1412.	3.2	32
283	Increased susceptibility of serum amyloid A 1.1 to degradation by MMP-1: potential explanation for higher risk of type AA amyloidosis. Rheumatology, 2008, 47, 1651-1654.	1.9	37
284	Lovastatin inhibits formation of AA amyloid. Journal of Leukocyte Biology, 2008, 83, 1295-1299.	3.3	17
285	Increase in prefrontal cortical volume following cognitive behavioural therapy in patients with chronic fatigue syndrome. Brain, 2008, 131, 2172-2180.	7.6	205
286	Differential function of the NACHT-LRR (NLR) members Nod1 and Nod2 in arthritis. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 9017-9022.	7.1	54
287	Functional Consequences of Toll-like Receptor 4 Polymorphisms. Molecular Medicine, 2008, 14, 346-352.	4.4	245
288	Guided self-instructions for people with chronic fatigue syndrome: randomised controlled trial. British Journal of Psychiatry, 2008, 193, 340-341.	2.8	82

#	Article	IF	Citations
289	Long-Term Follow-Up, Clinical Features, and Quality of Life in a Series of 103 Patients With Hyperimmunoglobulinemia D Syndrome. Medicine (United States), 2008, 87, 301-310.	1.0	344
290	Control Measures Used during Lymphogranuloma Venereum Outbreak, Europe. Emerging Infectious Diseases, 2008, 14, 573-578.	4.3	5
291	The Janus face of Bartonella quintana recognition by Toll-like receptors (TLRs): a review. European Cytokine Network, 2008, 19, 113-8.	2.0	12
292	50 years Netherlands Journal of Medicine - 2002, reshaping the journal. Netherlands Journal of Medicine, 2008, 66, 398-9.	0.5	0
293	NOD2 engagement induces proinflammatory cytokine production, but not apoptosis, in leukocytes isolated from patients with Crohn's disease. European Cytokine Network, 2008, 19, 185-9.	2.0	1
294	The role of TNF-Î± in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. Journal of Lipid Research, 2007, 48, 751-762.	4.2	580
295	Immune Recognition ofCandida albicansÎ²â€glucan by Dectinâ€1. Journal of Infectious Diseases, 2007, 196, 1565-1571.	4.0	277
296	TLR4polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 16645-16650.	7.1	293
297	Pathogenesis of familial periodic fever syndromes or hereditary autoinflammatory syndromes. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2007, 292, R86-R98.	1.8	118
298	The Effect of Acclydine in Chronic Fatigue Syndrome: A Randomized Controlled Trial. PLOS Clinical Trials, 2007, 2, e19.	3.5	16
299	Comment on: Schnitzlers syndrome exacerbation after anti-TNF treatment. Rheumatology, 2007, 46, 1741-1741.	1.9	7
300	A Prospective Multicenter Study on Fever of Unknown Origin. Medicine (United States), 2007, 86, 26-38.	1.0	321
301	Is a Full Recovery Possible after Cognitive Behavioural Therapy for Chronic Fatigue Syndrome?. Psychotherapy and Psychosomatics, 2007, 76, 171-176.	8.8	132
302	Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Annals of the Rheumatic Diseases, 2007, 66, 1503-1507.	0.9	136
303	Dynamic Changes in Pro- and Anti-Inflammatory Cytokine Profiles and Gamma Interferon Receptor Signaling Integrity Correlate with Tuberculosis Disease Activity and Response to Curative Treatment. Infection and Immunity, 2007, 75, 820-829.	2.2	147
304	Tailored Interventions to Improve Antibiotic Use for Lower Respiratory Tract Infections in Hospitals: A Cluster-Randomized, Controlled Trial. Clinical Infectious Diseases, 2007, 44, 931-941.	5.8	68
305	Bartonella quintanaLipopolysaccharide Is a Natural Antagonist of Toll-Like Receptor 4. Infection and Immunity, 2007, 75, 4831-4837.	2.2	76
306	Continuous administration of PBP-2- and PBP-3-specific Î²-lactams causes higher cytokine responses in murine Pseudomonas aeruginosa and Escherichia coli sepsis. Journal of Antimicrobial Chemotherapy, 2007, 59, 926-933.	3.0	24

#	Article	IF	Citations
307	Barriers to optimal antibiotic use for community-acquired pneumonia at hospitals: a qualitative study. Quality and Safety in Health Care, 2007, 16, 143-149.	2.5	95
308	Defective apoptosis of peripheral-blood lymphocytes in hyper-IgD and periodic fever syndrome. Blood, 2007, 109, 2416-2418.	1.4	36
309	MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) IN MENINGOCOCCAL SEPTIC SHOCK AND EXPERIMENTAL HUMAN ENDOTOXEMIA. Shock, 2007, 27, 482-487.	2.1	29
310	Is cognitive behaviour therapy for chronic fatigue syndrome also effective for pain symptoms?. Behaviour Research and Therapy, 2007, 45, 2034-2043.	3.1	47
311	Mycobacterium paratuberculosisis recognized by Toll-like receptors and NOD2. Journal of Leukocyte Biology, 2007, 82, 1011-1018.	3.3	133
312	The Effect of Type 2 Diabetes Mellitus on the Presentation and Treatment Response of Pulmonary Tuberculosis. Clinical Infectious Diseases, 2007, 45, 428-435.	5.8	270
313	Recognition of fungal pathogens by Toll-like receptors. , 2007, , 259-272.		8
314	Inhibition of tollâ€like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis. Arthritis and Rheumatism, 2007, 56, 2957-2967.	6.7	281
315	Dengue disease severity in Indonesian children: an evaluation of the World Health Organization classification system. BMC Infectious Diseases, 2007, 7, 22.	2.9	31
316	AL amyloidosis enhances development of amyloid A amyloidosis. British Journal of Dermatology, 2007, 156, 748-749.	1.5	12
317	Increased voluntary exercise in mice deficient for tumour necrosis factor-? and lymphotoxin-?. European Journal of Clinical Investigation, 2007, 37, 737-741.	3.4	11
318	The role of microbiology and pharmacy departments in the stewardship of antibiotic prescribing in European hospitals. Journal of Hospital Infection, 2007, 65, 73-81.	2.9	29
319	Schnitzler Syndrome: Beyond the Case Reports: Review and Follow-Up of 94 Patients with an Emphasis on Prognosis and Treatment. Seminars in Arthritis and Rheumatism, 2007, 37, 137-148.	3.4	228
320	A prospective multi-centre study of the value of FDG-PET as part of a structured diagnostic protocol in patients with fever of unknown origin. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 694-703.	6.4	182
321	The Inflammasome â€" A Linebacker of Innate Defense. New England Journal of Medicine, 2006, 355, 730-732.	27.0	115
322	LPS-Induced Release of IL-1Î², IL-1Ra, IL-6, and TNF-Î±in Whole Blood from Patients with Familial Hypercholesterolemia: No Effect of Cholesterol-Lowering Treatment. Journal of Interferon and Cytokine Research, 2006, 26, 101-107.	1.2	18
323	Chronic fatigue syndrome. Lancet, The, 2006, 367, 346-355.	13.7	604
324	Defective acute inflammation in Crohn's disease. Lancet, The, 2006, 368, 577-578.	13.7	2

#	Article	IF	Citations
325	Erratum to Letter to the Editor: â€œAnti-TNF therapy and plasma HDL cholesterol concentrationâ€• [Atherosclerosis 182 (2005) 375]. Atherosclerosis, 2006, 184, 458.	0.8	0
326	Beneficial response to anakinra and thalidomide in Schnitzler's syndrome. Annals of the Rheumatic Diseases, 2006, 65, 542-544.	0.9	126
327	Role of the dual interaction of fungal pathogens with pattern recognition receptors in the activation and modulation of host defence. Clinical Microbiology and Infection, 2006, 12, 404-409.	6.0	62
328	Pathophysiology of in-vitro induced filaments, spheroplasts and rod-shaped bacteria in neutropenic mice. Clinical Microbiology and Infection, 2006, 12, 1105-1111.	6.0	8
329	Public health implications of using various case definitions in The Netherlands during the worldwide SARS outbreak. Clinical Microbiology and Infection, 2006, 12, 1214-1220.	6.0	10
330	Critical aneurysmal dilatation of the thoracic aorta in young adolescents with variant hyperimmunoglobulin E syndrome. Journal of Internal Medicine, 2006, 259, 615-618.	6.0	12
331	Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. Nature Medicine, 2006, 12, 650-656.	30.7	360
332	Linkage of autosomal-dominant common variable immunodeficiency to chromosome 4q. European Journal of Human Genetics, 2006, 14, 867-875.	2.8	46
333	Both TLR2 and TLR4 are involved in the recognition of Candida albicans. Reply to â€œTLR2, but not TLR4, triggers cytokine production by murine cells in response to Candida albicans yeasts and hyphaeâ€•by Gil and Gozalbo, Microbes and Infection 8 (2006) 2823â€“2824. Microbes and Infection, 2006, 8, 2821-2822.	1.9	16
334	To the Editor. European Journal of Immunology, 2006, 36, 2817-2818.	2.9	2
335	Approach to genetic analysis in the diagnosis of hereditary autoinflammatory syndromes. Rheumatology, 2006, 45, 269-273.	1.9	79
336	Recognition of Fungal Pathogens by Toll-Like Receptors. Current Pharmaceutical Design, 2006, 12, 4195-4201.	1.9	116
337	The effect of cognitive behaviour therapy for chronic fatigue syndrome on self-reported cognitive impairments and neuropsychological test performance. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 78, 434-436.	1.9	24
338	Endogenous Interleukin (IL)â€“1Î± and ILâ€‰1Î² Are Crucial for Host Defense against Disseminated Candidiasis. Journal of Infectious Diseases, 2006, 193, 1419-1426.	4.0	150
339	Host defence against disseminatedCandida albicansinfection and implications for antifungal immunotherapy. Expert Opinion on Biological Therapy, 2006, 6, 891-903.	3.1	46
340	Nucleotide Oligomerization Domain 2 (Nod2) Is Not Involved in the Pattern Recognition of Candida albicans. Vaccine Journal, 2006, 13, 423-425.	3.1	34
341	Immune sensing of Candida albicans requires cooperative recognition of mannans and glucans by lectin and Toll-like receptors. Journal of Clinical Investigation, 2006, 116, 1642-1650.	8.2	632
342	Toll-like receptor 4 Asp299Gly/Thr399Ile polymorphisms are a risk factor for Candida bloodstream infection. European Cytokine Network, 2006, 17, 29-34.	2.0	125

#	Article	IF	Citations
343	Diabetes mellitus is strongly associated with tuberculosis in Indonesia. International Journal of Tuberculosis and Lung Disease, 2006, 10, 696-700.	1.2	108
344	Familial Mediterranean feverâ€"a not so unusual cause of abdominal pain. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2005, 19, 199-213.	2.4	41
345	Severely impaired IL-12/IL-18/IFNgamma axis in patients with hyper IgE syndrome. European Journal of Clinical Investigation, 2005, 35, 718-721.	3.4	35
346	Low plasma selenium concentrations, high plasma human immunodeficiency virus load and high interleukin-6 concentrations are risk factors associated with anemia in adults presenting with pulmonary tuberculosis in Zomba district, Malawi. European Journal of Clinical Nutrition, 2005, 59, 526-532.	2.9	76
347	Elevated plasma levels of the long pentraxin, pentraxin 3, in severe dengue virus infections. Journal of Medical Virology, 2005, 76, 547-552.	5.0	103
348	Interleukin-18 does not modulate the acute-phase response. Journal of Endotoxin Research, 2005, 11, 85-88.	2.5	13
349	NOD2 and Toll-Like Receptors Are Nonredundant Recognition Systems of Mycobacterium tuberculosis. PLoS Pathogens, 2005, 1, e34.	4.7	304
350	Quality of Antibiotic Use for Lower Respiratory Tract Infections at Hospitals: (How) Can We Measure It?. Clinical Infectious Diseases, 2005, 41, 450-460.	5.8	56
351	Markers of inflammation are negatively correlated with serum leptin in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2005, 64, 1195-1198.	0.9	141
352	Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Annals of the Rheumatic Diseases, 2005, 64, 303-305.	0.9	193
353	From the Th1/Th2 Paradigm towards a Toll-Like Receptor/T-Helper Bias. Antimicrobial Agents and Chemotherapy, 2005, 49, 3991-3996.	3.2	173
354	Serum amyloid A serum concentrations and genotype do not explain low incidence of amyloidosis in Hyper-IgD syndrome. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2005, 12, 115-119.	3.0	17
355	Nucleotide-Binding Oligomerization Domain-2 Modulates Specific TLR Pathways for the Induction of Cytokine Release. Journal of Immunology, 2005, 174, 6518-6523.	0.8	248
356	The Frameshift Mutation in Nod2 Results in Unresponsiveness Not Only to Nod2- but Also Nod1-activating Peptidoglycan Agonists. Journal of Biological Chemistry, 2005, 280, 35859-35867.	3.4	73
357	Differential Cytokine Production and Toll-Like Receptor Signaling Pathways by Candida albicans Blastoconidia and Hyphae. Infection and Immunity, 2005, 73, 7458-7464.	2.2	175
358	Cognitive Behaviour Group Therapy for Chronic Fatigue Syndrome: A Non-Randomised Waiting List Controlled Study. Psychotherapy and Psychosomatics, 2005, 74, 218-224.	8.8	40
359	Interleukin-6 and Human Immunodeficiency Virus Load, But Not Plasma Leptin Concentration, Predict Anorexia and Wasting in Adults with Pulmonary Tuberculosis in Malawi. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4771-4776.	3.6	44
360	Anti-TNF therapy and plasma HDL cholesterol concentration. Atherosclerosis, 2005, 182, 375.	0.8	3

#	Article	IF	Citations
361	Gray matter volume reduction in the chronic fatigue syndrome. NeuroImage, 2005, 26, 777-781.	4.2	146
362	Impact of a maximal exercise test on symptoms and activity in chronic fatigue syndrome. Journal of Psychosomatic Research, 2005, 59, 201-208.	2.6	44
363	Cytokine production of stimulated whole blood cultures in rheumatoid arthritis patients receiving short-term infliximab therapy. Cytokine, 2005, 30, 72-77.	3.2	21
364	Functional consequences of the Asp299Gly Toll-like receptor-4 polymorphism. Cytokine, 2005, 30, 264-268.	3.2	58
365	Response to Gil et al.: Toll-like receptor-2 â€“ an important component of host defense. Trends in Microbiology, 2005, 13, 299-300.	7.7	4
366	Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. Netherlands Journal of Medicine, 2005, 63, 260-4.	0.5	134
367	NOD2 3020insC mutation and the pathogenesis of Crohn's disease: impaired IL-1beta production points to a loss-of-function phenotype. Netherlands Journal of Medicine, 2005, 63, 305-8.	0.5	54
368	Development of a sensitive ELISA for the quantification of human tumour necrosis factor-alpha using 4 polyclonal antibodies. European Cytokine Network, 2005, 16, 215-22.	2.0	18
369	Complement Activation and Complement-Dependent Inflammation by Neisseria meningitidis Are Independent of Lipopolysaccharide. Infection and Immunity, 2004, 72, 3344-3349.	2.2	67
370	Neural correlates of the chronic fatigue syndrome–an fMRI study. Brain, 2004, 127, 1948-1957.	7.6	126
371	Toll-Like Receptor 2 Suppresses Immunity against Candida albicans through Induction of IL-10 and Regulatory T Cells. Journal of Immunology, 2004, 172, 3712-3718.	0.8	565
372	Two Patients with Cryptococcal Meningitis and Idiopathic CD4 Lymphopenia: Defective Cytokine Production and Reversal by Recombinant Interferon-Â Therapy. Clinical Infectious Diseases, 2004, 39, e83-e87.	5.8	93
373	Recombinant Interleukinâ€18 Protects against DisseminatedCandida albicansInfection in Mice. Journal of Infectious Diseases, 2004, 189, 1524-1527.	4.0	29
374	Monomeric IgG in Intravenous Ig Preparations Is a Functional Antagonist of FcÎ³RII and FcÎ³RIIIb. Journal of Immunology, 2004, 173, 332-339.	0.8	58
375	Social Support and the Persistence of Complaints in Chronic Fatigue Syndrome. Psychotherapy and Psychosomatics, 2004, 73, 174-182.	8.8	76
376	Chlamydia pneumoniaeStimulates IFN-Î³ Synthesis through MyD88-Dependent, TLR2- and TLR4-Independent Induction of IL-18 Release. Journal of Immunology, 2004, 173, 1477-1482.	0.8	43
377	Apolipoprotein-E-deficient mice exhibit an increased susceptibility to disseminated candidiasis. Medical Mycology, 2004, 42, 341-348.	0.7	29
378	Improving the Process of Antibiotic Therapy in Daily Practice. Archives of Internal Medicine, 2004, 164, 1206.	3.8	38

#	Article	IF	Citations
379	Human lipoproteins have divergent neutralizing effects on E. coli LPS, N. meningitidis LPS, and complete Gram-negative bacteria. Journal of Lipid Research, 2004, 45, 742-749.	4.2	21
380	Mevalonate kinase deficiency. Neurology, 2004, 62, 994-997.	1.1	142
381	Toll-like receptor-4 Asp299Gly polymorphism does not influence progression of atherosclerosis in patients with familial hypercholesterolaemia. European Journal of Clinical Investigation, 2004, 34, 94-99.	3.4	66
382	Dr Baschetti rides/writes again. European Journal of Clinical Investigation, 2004, 34, 317-317.	3.4	0
383	Toll-like receptor-4 Asp299Gly polymorphism does not influence progression of atherosclerosis in patients with familial hypercholesterolemia. European Journal of Clinical Investigation 2004;34:94-99. European Journal of Clinical Investigation, 2004, 34, 322-322.	3.4	0
384	Effect of inflammatory attacks in the classical type hyper-IgD syndrome on immunoglobulin D, cholesterol and parameters of the acute phase response. Journal of Internal Medicine, 2004, 256, 247-253.	6.0	34
385	Reply to: Chronic fatigue syndrome: a clinical and laboratory study with a well-matched control group. Journal of Internal Medicine, 2004, 256, 268-269.	6.0	3
386	Reduced production of immunoregulatory cytokines in vitamin A- and zinc-deficient Indonesian infants. European Journal of Clinical Nutrition, 2004, 58, 1498-1504.	2.9	57
387	Recognition of fungal pathogens by Toll-like receptors. European Journal of Clinical Microbiology and Infectious Diseases, 2004, 23, 672-6.	2.9	119
388	Fever of unknown origin: prospective comparison of diagnostic value of 18F-FDG PET and 111In-granulocyte scintigraphy. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 1342-1343.	6.4	14
389	Clinical value of FDG PET in patients with fever of unknown origin and patients suspected of focal infection or inflammation. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 29-37.	6.4	230
390	F-18-fluorodeoxyglucose positron emission tomography leading to a diagnosis of septic thrombophlebitis of the portal vein: description of a case history and review of the literature. Journal of Internal Medicine, 2004, 255, 419-423.	6.0	27
391	NOD2 mediates anti-inflammatory signals induced by TLR2 ligands: implications for Crohn's disease. European Journal of Immunology, 2004, 34, 2052-2059.	2.9	214
392	Human dendritic cells are less potent at killing Candida albicans than both monocytes and macrophages. Microbes and Infection, 2004, 6, 985-989.	1.9	53
393	Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clinical Pharmacology and Therapeutics, 2004, 75, 476-483.	4.7	190
394	Proinflammatory Cytokines in the Treatment of Bacterial and Fungal Infections. BioDrugs, 2004, 18, 9-22.	4.6	19
395	Toll-like receptors and the host defense against microbial pathogens: bringing specificity to the innate-immune system. Journal of Leukocyte Biology, 2004, 75, 749-755.	3.3	239
396	Mannose binding lectin enhances IL-1Î² and IL-10 induction by non-lipopolysaccharide (LPS) components of Neisseria meningitidis. Cytokine, 2004, 28, 59-66.	3.2	23

#	Article	IF	Citations
397	Toll-like receptors as an escape mechanism from the host defense. Trends in Microbiology, 2004, 12, 484-488.	7.7	201
398	Fluorine 18 fluorodeoxyglucose positron emission tomography in the diagnosis and follow-up of three patients with vasculitis. American Journal of Medicine, 2004, 116, 50-53.	1.5	49
399	Beneficial response to interleukin 1 receptor antagonist in traps. American Journal of Medicine, 2004, 117, 208-210.	1.5	146
400	Tissue- and Time-Dependent Upregulation of Cytokine mRNA in a Murine Model for the Multiple Organ Dysfunction Syndrome. Annals of Surgery, 2004, 240, 142-150.	4.2	23
401	Cost-effectiveness of cognitive behaviour therapy for patients with chronic fatigue syndrome. QJM - Monthly Journal of the Association of Physicians, 2004, 97, 153-161.	0.5	37
402	Giant chalazia in the hyperimmunoglobulinemia E (hyper-IgE) syndrome. European Journal of Ophthalmology, 2004, 14, 258-260.	1.3	2
403	Duration of Antifungal Treatment and Development of Delayed Complications in Patients with Candidaemia. European Journal of Clinical Microbiology and Infectious Diseases, 2003, 22, 43-48.	2.9	41
404	Differential role of IL-18 and IL-12 in the host defense against disseminatedCandida albicans infection. European Journal of Immunology, 2003, 33, 3409-3417.	2.9	49
405	Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Association with decreased interferon-? production and toll-like receptor 4 expression. Arthritis and Rheumatism, 2003, 48, 1853-1857.	6.7	111
406	Selecting outcome parameters in studies aimed at improving rational use of antibiotics - practical considerations. Journal of Clinical Pharmacy and Therapeutics, 2003, 28, 475-478.	1.5	4
407	Selective regulation of intercellular adhesion molecule-1 expression by interleukin-18 and interleukin-12 on human monocytes. Immunology, 2003, 110, 329-334.	4.4	53
408	Pneumococcal aortitis, report of a case with emphasis on the contribution to diagnosis of positron emission tomography using fluorinated deoxyglucose. Clinical Microbiology and Infection, 2003, 9, 73-76.	6.0	23
409	Circulating concentrations of soluble granzyme A and B increase during natural and experimental Plasmodium falciparum infections. Clinical and Experimental Immunology, 2003, 132, 467-472.	2.6	82
410	Leptin and proinflammatory cytokines in patients undergoing peritoneal dialysis. European Journal of Clinical Investigation, 2003, 33, 525-526.	3.4	4
411	A founder effect in the hyperimmunoglobulinemia D and periodic fever syndrome. American Journal of Medicine, 2003, 114, 148-152.	1.5	55
412	The role of clinical guidelines, policies and stewardship. Journal of Hospital Infection, 2003, 53, 172-176.	2.9	38
413	Proinflammatory cytokines and sepsis syndrome: not enough, or too much of a good thing?. Trends in Immunology, 2003, 24, 254-258.	6.8	171
414	Regulation of Staphylococcus epidermidis-induced IFN-Î³ in whole human blood: the role of endogenous IL-18, IL-12, IL-1, and TNF. Cytokine, 2003, 21, 65-73.	3.2	24

#	Article	IF	Citations
415	Hypoglycaemia downregulates endotoxin-induced production of tumour necrosis factor-Î±, but does not affect IL-1Î², IL-6, or IL-10. Cytokine, 2003, 22, 71-76.	3.2	14
416	Chemical Sensitivity in Symptomatic Cambodia Veterans. Archives of Environmental Health, 2003, 58, 740-745.	0.4	1
417	Treatment of Intra-Abdominal Abscesses Caused by Candida albicans with Antifungal Agents and Recombinant Murine Granulocyte Colony-Stimulating Factor. Antimicrobial Agents and Chemotherapy, 2003, 47, 3688-3693.	3.2	8
418	Aspergillus fumigatusEvades Immune Recognition during Germination through Loss of Tollâ€Like Receptorâ€4â€“Mediated Signal Transduction. Journal of Infectious Diseases, 2003, 188, 320-326.	4.0	290
419	Persistence of Salmonellae in Blood and Bone Marrow: Randomized Controlled Trial Comparing Ciprofloxacin and Chloramphenicol Treatments against Enteric Fever. Antimicrobial Agents and Chemotherapy, 2003, 47, 1727-1731.	3.2	34
420	Inhibition of C5a-induced inflammation with preserved C5b-9-mediated bactericidal activity in a human whole blood model of meningococcal sepsis. Blood, 2003, 102, 3702-3710.	1.4	99
421	Redistribution of vitamin A after iron supplementation in Indonesian infants. American Journal of Clinical Nutrition, 2003, 77, 651-657.	4.7	56
422	Pro-Inflammatory Cytokine Response in Acute Infection. Advances in Experimental Medicine and Biology, 2003, 531, 229-240.	1.6	3
423	Innate Immunity to Mycobacterium Tuberculosis. Advances in Experimental Medicine and Biology, 2003, 531, 241-247.	1.6	29
424	Micronutrient Deficiency and Supplementation in Indonesian Infants. Advances in Experimental Medicine and Biology, 2003, 531, 369-377.	1.6	6
425	Candida-specific interferon-gamma deficiency and toll-like receptor polymorphisms in patients with chronic mucocutaneous candidiasis. Netherlands Journal of Medicine, 2003, 61, 365-9.	0.5	23
426	The Role of Tollâ€like Receptor (TLR) 2 and TLR4 in the Host Defense against Disseminated Candidiasis. Journal of Infectious Diseases, 2002, 185, 1483-1489.	4.0	444
427	The Role of Endogenous Interleukin (IL)â€“18, ILâ€12, ILâ€1Î², and Tumor Necrosis Factorâ€“Î± in the Production of Interferonâ€Î³ Induced byCandida albicansin Human Wholeâ€Blood Cultures. Journal of Infectious Diseases, 2002, 185, 963-970.	4.0	67
428	Decreased Plasma Leptin Concentrations in Tuberculosis Patients Are Associated with Wasting and Inflammation. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 758-763.	3.6	107
429	Delayed Clearance of Intraabdominal Abscesses Caused byCandida albicansin Tumor Necrosis Factorâ€“Î±â€“ and Lymphotoxinâ€Î±â€“Deficient Mice. Journal of Infectious Diseases, 2002, 186, 1815-1822.	4.0	32
430	Native LDL potentiate TNFÎ± and IL-8 production by human mononuclear cells. Journal of Lipid Research, 2002, 43, 1065-1071.	4.2	15
431	Role of Interleukin-18 in Host Defense against Disseminated Candida albicans Infection. Infection and Immunity, 2002, 70, 3284-3286.	2.2	46
432	The effect of a polynutrient supplement on fatigue and physical activity of patients with chronic fatigue syndrome: a double-blind randomized controlled trial. QJM - Monthly Journal of the Association of Physicians, 2002, 95, 677-683.	0.5	52

#	Article	IF	Citations
433	A double-blind, placebo-controlled study of vitamin A and zinc supplementation in persons with tuberculosis in Indonesia: effects on clinical response and nutritional status. American Journal of Clinical Nutrition, 2002, 75, 720-727.	4.7	150
434	Changes in the Plasma Lipid Profile as a Potential Predictor of Clinical Outcome in Dengue Hemorrhagic Fever. Clinical Infectious Diseases, 2002, 34, 1150-1153.	5.8	66
435	THE INFLUENCE OF DIETARY FISH-OIL SUPPLEMENTATION ON CUTANEOUS LEISHMANIA AMAZONENSIS INFECTION IN MICE. Cytokine, 2002, 19, 213-217.	3.2	2
436	TNFÎ± AND IL-1Î² EXERT NO DIRECT VASOACTIVITY IN HUMAN ISOLATED RESISTANCE ARTERIES. Cytokine, 2002, 20, 244-246.	3.2	7
437	Innate Immunity toMycobacterium tuberculosis. Clinical Microbiology Reviews, 2002, 15, 294-309.	13.6	511
438	Chronic fatigue syndrome and myalgic encephalomyelitis. Lancet, The, 2002, 359, 1699.	13.7	6
439	Natural course and predicting self-reported improvement in patients with chronic fatigue syndrome with a relatively short illness duration. Journal of Psychosomatic Research, 2002, 53, 749-753.	2.6	54
440	Does the shape of lipid A determine the interaction of LPS with Toll-like receptors?. Trends in Immunology, 2002, 23, 135-139.	6.8	242
441	Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia. International Journal of Tuberculosis and Lung Disease, 2002, 6, 497-502.	1.2	57
442	The Role of Post-Traumatic Stress Disorder Symptoms in Fatigued Cambodia Veterans. Military Medicine, 2002, 167, 790-794.	0.8	10
443	Physical activity and exercise performance in symptomatic Cambodia veterans. QJM - Monthly Journal of the Association of Physicians, 2002, 95, 99-105.	0.5	0
444	HLA-DRB1*12 is associated with protection against complicated typhoid fever, independent of tumour necrosis factor Î±. International Journal of Immunogenetics, 2002, 29, 297-300.	1.2	17
445	Non-LPS components ofChlamydia pneumoniae stimulate cytokine production through Toll-like receptor 2-dependent pathways. European Journal of Immunology, 2002, 32, 1188-1195.	2.9	103
446	CD40/CD40 ligand interactions in the host defense against disseminated Candida albicans infection: the role of macrophage-derived nitric oxide. European Journal of Immunology, 2002, 32, 1455.	2.9	50
447	Impaired fibrinolysis in the pathogenesis of dengue hemorrhagic fever. Journal of Medical Virology, 2002, 67, 549-554.	5.0	35
448	Hemodynamic and neurohumoral responses to head-up tilt in patients with chronic fatigue syndrome. Clinical Autonomic Research, 2002, 12, 273-280.	2.5	48
449	Failure of prescribers to adjust antibiotic dose to impaired renal function in daily clinical practice. British Journal of Clinical Pharmacology, 2002, 53, 557P-557P.	2.4	0
450	Non-LPS components of Chlamydia pneumoniae stimulate cytokine production through Toll-like receptor 2-dependent pathways. European Journal of Immunology, 2002, 32, 1188-1195.	2.9	4

#	Article	IF	Citations
451	Th1/Th2 cytokine imbalance in a family with hyper-IgE syndrome. Netherlands Journal of Medicine, 2002, 60, 349-53.	0.5	22
452	Familial periodic fever and amyloidosis due to a new mutation in the TNFRSF1A gene. American Journal of Medicine, 2001, 110, 313-316.	1.5	40
453	Cognitive behaviour therapy for chronic fatigue syndrome: a multicentre randomised controlled trial. Lancet, The, 2001, 357, 841-847.	13.7	472
454	Hereditary Periodic Fever. New England Journal of Medicine, 2001, 345, 1748-1757.	27.0	428
455	Natural course of symptoms in Cambodia veterans: a follow-up study. Psychological Medicine, 2001, 31, 331-338.	4.5	15
456	Is physical deconditioning a perpetuating factor in chronic fatigue syndrome? A controlled study on maximal exercise performance and relations with fatigue, impairment and physical activity. Psychological Medicine, 2001, 31, 107-114.	4.5	91
457	Molecular Analysis of the Mevalonate Kinase Gene in a Cohort of Patients with the Hyper-IgD and Periodic Fever Syndrome: Its Application as a Diagnostic Tool. Annals of Internal Medicine, 2001, 135, 338.	3.9	81
458	The Effect of Two Different Dosages of Intravenous Immunoglobulin on the Incidence of Recurrent Infections in Patients with Primary Hypogammaglobulinemia. Annals of Internal Medicine, 2001, 135, 165.	3.9	213
459	Pro-inflammatory cytokines in patients with essential hypertension. European Journal of Clinical Investigation, 2001, 31, 31-36.	3.4	121
460	LethalEscherichia coli andSalmonella typhimurium endotoxemia is mediated through different pathways. European Journal of Immunology, 2001, 31, 2529-2538.	2.9	42
461	Molecular analysis of MVK mutations and enzymatic activity in hyper-IgD and periodic fever syndrome. European Journal of Human Genetics, 2001, 9, 260-266.	2.8	182
462	Hyper-Immunoglobulin A in the Hyperimmunoglobulinemia D Syndrome. Vaccine Journal, 2001, 8, 58-61.	2.6	51
463	In Vivo Efficacy of Trovafloxacin against Bacteroides fragilis in Mixed Infection with either Escherichia coli or a Vancomycin-Resistant Strain of Enterococcus faecium in an Established-Abscess Murine Model. Antimicrobial Agents and Chemotherapy, 2001, 45, 1394-1401.	3.2	17
464	Differential Roles of Interleukin-18 (IL-18) and IL-12 for Induction of Gamma Interferon by Staphylococcal Cell Wall Components and Superantigens. Infection and Immunity, 2001, 69, 5025-5030.	2.2	26
465	Lethal Escherichia coli and Salmonella typhimurium endotoxemia is mediated through different pathways. European Journal of Immunology, 2001, 31, 2529.	2.9	1
466	The effect of salicylates on insulin sensitivity. Journal of Clinical Investigation, 2001, 108, 1723-1724.	8.2	8
467	Poor Micronutrient Status of Active Pulmonary Tuberculosis Patients in Indonesia. Journal of Nutrition, 2000, 130, 2953-2958.	2.9	136
468	Acellular components ofChlamydia pneumoniae stimulate cytokine production in human blood mononuclear cells. European Journal of Immunology, 2000, 30, 541-549.	2.9	93

#	Article	IF	Citations
469	Interleukin-18 induces production of proinflammatory cytokines in mice: no intermediate role for the cytokines of the tumor necrosis factor family and interleukin-1Î². European Journal of Immunology, 2000, 30, 3057-3060.	2.9	114
470	Circulating Cytokines as Mediators of Fever. Clinical Infectious Diseases, 2000, 31, S178-S184.	5.8	283
471	Hemofiltration in septic patients is not able to alter the plasma concentration of cytokines therapeutically. Intensive Care Medicine, 2000, 26, 1176-1178.	8.2	28
472	Scintigraphic detection of acute experimental endocarditis with the technetium-99m labelled glycoprotein IIb/IIIa receptor antagonist DMP444. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 392-399.	6.4	23
473	Earlier Initiation of Antibiotic Treatment for Severe Infections After Interventions to Improve the Organization and Specific Guidelines in the Emergency Department. Archives of Internal Medicine, 2000, 160, 1317.	3.8	23
474	Update on Meningococcal Disease with Emphasis on Pathogenesis and Clinical Management. Clinical Microbiology Reviews, 2000, 13, 144-166.	13.6	485
475	An IFN-Î³-Independent Proinflammatory Role of IL-18 in Murine Streptococcal Cell Wall Arthritis. Journal of Immunology, 2000, 165, 6553-6558.	0.8	114
476	Neutralization of IL-18 Reduces Neutrophil Tissue Accumulation and Protects Mice Against Lethal Escherichia coli and Salmonella typhimurium Endotoxemia. Journal of Immunology, 2000, 164, 2644-2649.	0.8	205
477	Antibiotic use in Dutch hospitals 1991â€“1996. Journal of Antimicrobial Chemotherapy, 2000, 45, 251-256.	3.0	52
478	ENTEROVIRUS-INDUCED PRODUCTION OF PRO-INFLAMMATORY AND T-HELPER CYTOKINES BY HUMAN LEUKOCYTES. Cytokine, 2000, 12, 1793-1796.	3.2	32
479	Identifying physical activity patterns in chronic fatigue syndrome using actigraphic assessment. Journal of Psychosomatic Research, 2000, 49, 373-379.	2.6	179
480	Acellular components of Chlamydia pneumoniae stimulate cytokine production in human blood mononuclear cells. , 2000, 30, 541.		2
481	Increased susceptibility to systemic candidiasis in interleukin-6 deficient mice 1. Medical Mycology, 1999, 37, 419-426.	0.7	62
482	Fasâ€FasL Interactions Modulate Host Defense against SystemicCandida albicansInfection. Journal of Infectious Diseases, 1999, 180, 1648-1655.	4.0	18
483	Infusion of Lipoproteins into Volunteers Enhances the Growth of Candida albicans. Clinical Infectious Diseases, 1999, 28, 1148-1151.	5.8	17
484	Immunomodulation by n-3 polyunsaturated fatty acids. Trends in Immunology, 1999, 20, 103.	7.5	6
485	Whole-blood cultures: a valid and reliable tool for studying cytokines in exercise. European Journal of Clinical Investigation, 1999, 29, 182-183.	3.4	0
486	Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. Nature Genetics, 1999, 22, 178-181.	21.4	511

#	Article	IF	Citations
487	Autonomic function in patients with chronic fatigue syndrome. Clinical Autonomic Research, 1999, 9, 334-340.	2.5	50
488	Disease-specific ex vivo stimulation of whole blood for cytokine production: applications in the study of tuberculosis. Journal of Immunological Methods, 1999, 222, 145-153.	1.4	44
489	Nuclear medicine's role in infection and inflammation. Lancet, The, 1999, 354, 765-770.	13.7	99
490	INTERLEUKIN 10 MITIGATES THE DEVELOPMENT OF THE ZYMOSAN-INDUCED MULTIPLE ORGAN DYSFUNCTION SYNDROME IN MICE. Cytokine, 1999, 11, 713-721.	3.2	20
491	Apolipoprotein E knock-out mice are highly susceptible to endotoxemia and Klebsiella pneumoniae infection. Journal of Lipid Research, 1999, 40, 680-685.	4.2	176
492	Imaging Experimental Intraabdominal Abscesses With 99mTc-PEG Liposomes and 99mTc-HYNIC IgG. Annals of Surgery, 1999, 229, 551-557.	4.2	30
493	Act now on antibiotic resistance. Nature Medicine, 1998, 4, 985-985.	30.7	1
494	Proinflammatory Cytokines and Treatment of Disease. Annals of the New York Academy of Sciences, 1998, 856, 243-251.	3.8	26
495	Application of the ATC/DDD methodology to monitor antibiotic drug use. European Journal of Clinical Microbiology and Infectious Diseases, 1998, 17, 20-24.	2.9	102
496	Delay in Administering the First Dose of Antibiotics in Patients Admitted to Hospital with Serious Infections. European Journal of Clinical Microbiology and Infectious Diseases, 1998, 17, 681-684.	2.9	41
497	Imaging of infection in rabbits with radioiodinated interleukin-1 (Î± and Î²), its receptor antagonist and a chemotactic peptide: a comparative study. European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25, 347-352.	6.4	38
498	Scintigraphic detection of infection and inflammation: new developments with special emphasis on receptor interaction. European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25, 535-546.	6.4	36
499	A normal platelet count at admission in acute meningococcal disease does not exclude a fulminant course. Intensive Care Medicine, 1998, 24, 157-161.	8.2	19
500	The effect of reninâ€“angiotensin system inhibitors on proâ€•and antiâ€•inflammatory cytokine production. Immunology, 1998, 94, 376-379.	4.4	93
501	Lipopolysaccharideâ€•induced production of tumour necrosis factor and interleukinâ€1 is differentially regulated at the receptor level: the role of CD14â€•dependent and CD14â€•independent pathways. Immunology, 1998, 94, 340-344.	4.4	25
502	BACTERIAL LIPOPOLYSACCHARIDE BINDS AND STIMULATES CYTOKINE-PRODUCING CELLS BEFORE NEUTRALIZATION BY ENDOGENOUS LIPOPROTEINS CAN OCCUR. Cytokine, 1998, 10, 766-772.	3.2	58
503	A MONOCLONAL ANTIBODY AGAINST TUMOUR NECROSIS FACTOR-Î± IMPROVES SURVIVAL IN EXPERIMENTAL MULTIPLE ORGAN DYSFUNCTION SYNDROME. Cytokine, 1998, 10, 904-910.	3.2	31
504	Functional and morphological monocyte abnormalities in a patient with malakoplakia. American Journal of Medicine, 1998, 105, 74-77.	1.5	76

#	Article	IF	Citations
505	LPS-induced cytokine production and expression of LPS-receptors by peripheral blood mononuclear cells of patients with familial hypercholesterolemia and the effect of HMG-CoA reductase inhibitors. Atherosclerosis, 1998, 139, 147-152.	0.8	49
506	LPS-induced cytokine production and expression of Î²2-integrins and CD14 by peripheral blood mononuclear cells of patients with homozygous familial hypercholesterolemia. Atherosclerosis, 1998, 141, 99-105.	0.8	31
507	Recombinant Murine Granulocyte Colonyâ€Stimulating Factor Protects against Acute DisseminatedCandida albicansInfection in Nonneutropenic Mice. Journal of Infectious Diseases, 1998, 177, 175-181.	4.0	56
508	Pathogenesis of Fever: Are Circulating Pyrogenic Cytokines the Only Mediators?. Clinical Infectious Diseases, 1998, 26, 1479-1479.	5.8	2
509	Modulation of the pro- and anti-inflammatory cytokine balance by amphotericin B. Journal of Antimicrobial Chemotherapy, 1998, 42, 469-474.	3.0	39
510	Plasma Patterns of Tumor Necrosis Factorâ€Î± (TNF) and TNF Soluble Receptors During Acute Meningococcal Infections and the Effect of Plasma Exchange. Clinical Infectious Diseases, 1998, 26, 918-923.	5.8	35
511	Increased interleukin-1Î± and interleukin-1Î² production by macrophages of low-density lipoprotein receptor knock-out mice stimulated with lipopolysaccharide is CD11c/CD18-receptor mediated. Immunology, 1998, 95, 466.	4.4	18
512	Chlorpromazine down-regulates tumor necrosis factor-alpha and attenuates experimental multiple organ dysfunction syndrome in mice. Critical Care Medicine, 1998, 26, 1244-1250.	0.9	18
513	Lipoprotein(a) Inhibits Lipopolysaccharide-Induced Tumor Necrosis Factor Alpha Production by Human Mononuclear Cells. Infection and Immunity, 1998, 66, 2365-2367.	2.2	26
514	Circulating and Ex Vivo Production of Pyrogenic Cytokines and Interleukin-1 Receptor Antagonist in 123 Patients with Fever of Unknown Origin. Journal of Infectious Diseases, 1997, 175, 191-194.	4.0	18
515	Technetium-99m labelled liposomes to image experimental arthritis. Annals of the Rheumatic Diseases, 1997, 56, 369-373.	0.9	41
516	Fever of Unknown Origin (FUO): I. A prospective multicenter study of 167 patients with FUO, using fixed epidemiologic entry criteria. Medicine (United States), 1997, 76, 392-400.	1.0	254
517	Fever of unknown origin (FUO): II. Diagnostic procedures in a prospective multicenter study of 167 patients. Medicine (United States), 1997, 76, 401-414.	1.0	124
518	International experts recommend concerted attack against infection. Lancet, The, 1997, 349, 184.	13.7	0
519	INTERLEUKIN 1Î², TUMOUR NECROSIS FACTOR-Î± AND INTERLEUKIN 1 RECEPTOR ANTAGONIST IN NEWLY DIAGNOSED INSULIN-DEPENDENT DIABETES MELLITUS: COMPARISON TO LONG-STANDING DIABETES AND HEALTHY INDIVIDUALS. Cytokine, 1997, 9, 284-287.	3.2	40
520	REGULATION OF THE PRODUCTION OF PRO-INFLAMMATORY CYTOKINES AND ANTAGONISTS DURING CHEMOTHERAPY-INDUCED NEUTROPENIA IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES. Cytokine, 1997, 9, 702-710.	3.2	16
521	The Role of Hyperuricemia in the Increased Cytokine Production After Lipopolysaccharide Challenge in Neutropenic Mice. Blood, 1997, 89, 577-582.	1.4	129
522	Implementation of an educational program and an antibiotic order form to optimize quality of antimicrobial drug use in a department of internal medicine. European Journal of Clinical Microbiology and Infectious Diseases, 1997, 16, 904-912.	2.9	48

#	Article	IF	Citations
523	Cytokine profiles in bronchoalveolar lavage fluid and blood in HIVâ€seropositive patients with Pneumocystis carinii pneumonia. European Journal of Clinical Investigation, 1997, 27, 333-339.	3.4	22
524	Pro- and anti-inflammatory cytokines in healthy volunteers fed various doses of fish oil for 1 year. European Journal of Clinical Investigation, 1997, 27, 1003-1008.	3.4	120
525	The effects of dexamethasone and chlorpromazine on tumour necrosis factorâ€•α , interleukinâ€1 β , interleukinâ€1 receptor antagonist and interleukinâ€10 in human volunteers. Immunology, 1997, 91, 548-552.	4.4	35
526	An unusual case of severe combined immunodeficiency with hypereosinophilia. Journal of Internal Medicine, 1997, 242, 267-269.	6.0	3
527	Lymphocyte Subsets, Apoptosis, and Cytokines in Patients with Chronic Fatigue Syndrome. Journal of Infectious Diseases, 1996, 173, 460-463.	4.0	87
528	A SEMI-QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION METHOD FOR MEASUREMENT OF MRNA FOR TNF-Î± AND IL-1Î² IN WHOLE BLOOD CULTURES: ITS APPLICATION IN TYPHOID FEVER AND EXENTRIC EXERCISE. Cytokine, 1996, 8, 739-744.	3.2	34
529	Effects of antirheumatic agents on cytokines. Seminars in Arthritis and Rheumatism, 1996, 25, 234-253.	3.4	57
530	Macrophage targeting in experimental arthritis. European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 727-727.	2.1	0
531	Technetium-99m labelled hydrazinonicotinamido human non-specific polyclonal immunoglobulin G for detection of infectious foci: a comparison with two other technetium-labelled immunoglobulin preparations. European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 414-421.	2.1	33
532	The uptake mechanisms of inflammation-and infection-localizing agents. European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 459-465.	2.1	36
533	Optimizing the timing of antimicrobial prophylaxis in surgery: an intervention study. Journal of Antimicrobial Chemotherapy, 1996, 38, 301-308.	3.0	46
534	Labelled StealthR liposomes in experimental infection. Nuclear Medicine Communications, 1996, 17, 742-748.	1.1	33
535	Modulation of Inflammation and Cytokine Production by Dietary (n-3) Fatty Acids. Journal of Nutrition, 1996, 126, 1515-1533.	2.9	202
536	Pro-inflammatory cytokines in lung and blood during steroid-induced Pneumocystis carinii pneumonia in rats. Journal of Leukocyte Biology, 1996, 60, 710-715.	3.3	29
537	Feasibility of an antibiotic order form. First experience in the department of internal medicine of a university hospital. International Journal of Clinical Pharmacy, 1996, 18, 137-141.	1.4	7
538	Increasing Cytotoxic Activity and Production of Reactive Oxygen and Nitrogen Intermediates by Peritoneal Macrophages During the Development of Multiple Organ Dysfunction Syndrome in Mice. Scandinavian Journal of Immunology, 1996, 44, 361-368.	2.7	10
539	Cytokine profiles in bronchoalveolar lavage fluid and blood in HIV-seronegative patients with Pneumocystis carinii pneumonia. European Journal of Clinical Investigation, 1996, 26, 159-166.	3.4	19
540	Immunoglobulin D enhances the release of tumour necrosis factorâ€Î±, and interleukinâ€1Î² as well as interleukinâ€1 receptor antagonist from human mononuclear cells. Immunology, 1996, 88, 355-362.	4.4	78

#	Article	IF	Citations
541	Optimising antimicrobial drug use in surgery: an intervention study in a Dutch university hospital. Journal of Antimicrobial Chemotherapy, 1996, 38, 1001-1012.	3.0	45
542	Recurrent Erysipelas or Erysipelas-like Rash?. Clinical Infectious Diseases, 1996, 22, 881-881.	5.8	4
543	Anti-toxoplasma effect of pyrimethamine, trimethoprim and sulphonamides alone and in combination: implications for therapy. Journal of Antimicrobial Chemotherapy, 1996, 38, 75-80.	3.0	42
544	Adverse reactions to co-trimoxazole in HIV infection: A reappraisal of the glutathione-hydroxylamine hypothesis. Journal of Antimicrobial Chemotherapy, 1996, 37, 55-60.	3.0	21
545	Inflammatory cytokines in an experimental model for the multiple organ dysfunction syndrome. Critical Care Medicine, 1996, 24, 1196-1202.	0.9	76
546	Low-density lipoprotein receptor-deficient mice are protected against lethal endotoxemia and severe gram-negative infections.. Journal of Clinical Investigation, 1996, 97, 1366-1372.	8.2	194
547	Interferonâ€î³ and urine neopterin in attacks of the hyperimmunoglobulinaemia D and periodic fever syndrome. European Journal of Clinical Investigation, 1995, 25, 683-686.	3.4	30
548	Chronic fatigue syndrome: a clinical and laboratory study with a well matched control group. Journal of Internal Medicine, 1995, 237, 499-506.	6.0	66
549	Metastatic breast cancer presenting as fever, rash, and arthritis. Cancer, 1995, 75, 1608-1611.	4.1	23
550	Dissociation of indium from indium-111-labelled diethylene triamine penta-acetic acid conjugated non-specific polyclonal human immunoglobulin G in inflammatory foci. European Journal of Nuclear Medicine and Molecular Imaging, 1995, 22, 212-219.	2.1	29
551	Serial indium-111-labelled IgG biodistribution in ratPneumocystis carinii pneumonia: a tool to monitor the course and severity of the infection. European Journal of Nuclear Medicine and Molecular Imaging, 1995, 22, 1129-1132.	2.1	3
552	Specific targeting of infectious foci with radioiodinated human recombinant interleukin-1 in an experimental model. European Journal of Nuclear Medicine and Molecular Imaging, 1995, 22, 1249-1255.	2.1	46
553	Elevated Serum Level and Altered Glycosylation of Î±1-Acid Glycoprotein in Hyperimmunoglobulinemia D and Periodic Fever Syndrome: Evidence for Persistent Inflammation. Clinical Immunology and Immunopathology, 1995, 76, 279-284.	2.0	27
554	Epstein-Barr Virus (EBV) and the Chronic Fatigue Syndrome: Normal Virus Load in Blood and Normal Immunologic Reactivity in the EBV Regression Assay. Clinical Infectious Diseases, 1995, 20, 1390-1392.	5.8	43
555	Correlation between Proinflammatory Cytokines and Antiinflammatory Mediators and the Severity of Disease in Meningococcal Infections. Journal of Infectious Diseases, 1995, 172, 433-439.	4.0	241
556	Viral Antibodies in Chronic Fatigue Syndrome. Clinical Infectious Diseases, 1995, 21, 708-709.	5.8	5
557	Treatment of Otitis Media. Clinical Infectious Diseases, 1995, 21, 1069-1069.	5.8	0
558	Phospholipase A2 Is a Circulating Mediator in Typhoid Fever. Journal of Infectious Diseases, 1995, 172, 305-308.	4.0	26

#	Article	IF	Citations
559	Circulating Interleukin-6 Receptor in Patients with Sepsis Syndrome. Journal of Infectious Diseases, 1995, 171, 469-472.	4.0	94
560	Pharmacologic Inhibitors of Tumor Necrosis Factor Production Exert Differential Effects in Lethal Endotoxemia and in Infection with Live Microorganisms in Mice. Journal of Infectious Diseases, 1995, 171, 393-399.	4.0	72
561	Inhibition of Plasmodium berghei Liver Schizont Development and Reduction of Cytokine Production Capacity in Rats by Dietary Fish Oil Supplementation. American Journal of Tropical Medicine and Hygiene, 1995, 53, 206-210.	1.4	7
562	Sequential therapy with intravenous and oral cephalosporins. Journal of Antimicrobial Chemotherapy, 1994, 33, 169-177.	3.0	42
563	Patterns of Proinflammatory Cytokines and Inhibitors during Typhoid Fever. Journal of Infectious Diseases, 1994, 169, 1306-1311.	4.0	91
564	Enteroviruses and the Chronic Fatigue Syndrome. Clinical Infectious Diseases, 1994, 19, 860-864.	5.8	56
565	Differential Expression of Proinflammatory Cytokines and Their Inhibitors during the Course of Meningococcal Infections. Journal of Infectious Diseases, 1994, 169, 157-161.	4.0	173
566	Introduction: Cytokines in the biotherapy of infectious diseases. Biotherapy (Dordrecht, Netherlands), 1994, 7, 149-150.	0.7	1
567	Interleukin-1 and related pro-inflammatory cytokines in the treatment of bacterial infections in neutropenic and non-neutropenic animals. Biotherapy (Dordrecht, Netherlands), 1994, 7, 161-167.	0.7	10
568	Location of the gene causing hyperimmunoglobulinemia D and periodic fever syndrome differs from that for familial mediterranean fever. Human Genetics, 1994, 94, 616-620.	3.8	36
569	Dimensional assessment of chronic fatigue syndrome. Journal of Psychosomatic Research, 1994, 38, 383-392.	2.6	1,049
570	Acute Renal Failure Associated with Paracetamol digestion in an Alcoholic Patient. Nephron, 1994, 67, 483-485.	1.8	5
571	Hyperimmunoglobulinemia D and Periodic Fever Syndrome. Medicine (United States), 1994, 73, 133-144.	1.0	346
572	Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor Î±, and interleukin-6 levels in rheumatoid arthritis.. Arthritis and Rheumatism, 1993, 36, 1070-1079.	6.7	137
573	Specific antibody uptake in tuberculosis?. European Journal of Nuclear Medicine and Molecular Imaging, 1993, 20, 568-569.	2.1	4
574	Reflex sympathetic dystrophy of the hand: an excessive inflammatory response?. Pain, 1993, 55, 151-157.	4.2	187
575	Cytokine Release in an Ovarian Carcinoma Patient Following Intravenous Administration of Bispecific Antibody OC/TR F(ab')2. Journal of the National Cancer Institute, 1993, 85, 1003-1004.	6.3	25
576	Cytokine Patterns in Patients After Major Vascular Surgery, Hemorrhagic Shock, and Severe Blunt Trauma Relation with Subsequent Adult Respiratory Distress Syndrome and Multiple Organ Failure. Annals of Surgery, 1993, 218, 769-776.	4.2	575

#	Article	IF	Citations
577	Plasma and Whole Blood Exchange in Meningococcal Sepsis. Clinical Infectious Diseases, 1992, 15, 424-430.	5.8	123
578	Indium-111-Labeled Human Nonspecific Immunoglobulin G: A New Radiopharmaceutical for Imaging Infectious and Inflammatory Foci. Clinical Infectious Diseases, 1992, 14, 1110-1118.	5.8	39
579	Optimizing antimicrobial therapy. A method for antimicrobial drug me evaluation. Journal of Antimicrobial Chemotherapy, 1992, 30, 724-727.	3.0	87
580	Chronic intraperitoneal infusion of low doses of tumor necrosis factor Î± in rats induces a reduction in plasma triglyceride levels. Cytokine, 1992, 4, 561-567.	3.2	13
581	Dietary Fish-Oil Supplementation in Experimental Gram-Negative Infection and in Cerebral Malaria in Mice. Journal of Infectious Diseases, 1992, 165, 898-903.	4.0	100
582	Prevention of viridans-group streptococcal septicemia in oncohematologic patients: A controlled comparative study on the effect of penicillin G and cotrimoxazole. Annals of Hematology, 1992, 64, 260-265.	1.8	28
583	Cytokines and the response to infection. Journal of Pathology, 1992, 168, 349-356.	4.5	142
584	Erysipelas-like skin lesions associated withCampylobacter jejuni septicemia in patients with hypogammaglobulinemia. European Journal of Clinical Microbiology and Infectious Diseases, 1992, 11, 842-847.	2.9	67
585	Selective digestive decontamination in intensive care unit patients. Intensive Care Medicine, 1992, 18, 182-188.	8.2	43
586	Relapsing hepatitis due to cytomegalovirus?. Journal of Infection, 1991, 23, 175-178.	3.3	3
587	Cost of hospital antimicrobial chemotherapy. Pharmaceutisch Weekblad, 1991, 13, 248-253.	0.7	19
588	Decreased natural killer cell activity in late-onset hypogammaglobulinaemia. Clinical Science, 1990, 78, 133-137.	4.3	5
589	Respiratory failure elicited by streptococcal septicaemia in patients treated with cytosine arabinoside, and its prevention by penicillin. Infection, 1990, 18, 131-137.	4.7	45
590	Treatment of invasive aspergillosis with itraconazole in a patient with chronic granulomatous disease. Journal of Infection, 1990, 20, 147-150.	3.3	25
591	Circulating Interleukin-1 and Tumor Necrosis Factor in Septic Shock and Experimental Endotoxin Fever. Journal of Infectious Diseases, 1990, 161, 79-84.	4.0	755
592	Interleukin-l Induces Tumor Necrosis Factor (TNF) in Human Peripheral Blood Mononuclear Cells In Vitro and a Circulating TNF-like Activity in Rabbits. Journal of Infectious Diseases, 1990, 162, 215-223.	4.0	116
593	The effects of recombinant interleukin-1 and recombinant tumor necrosis factor on non-specific resistance to infection. Biotherapy (Dordrecht, Netherlands), 1989, 1, 19-25.	0.7	50
594	Thein vivo andin vitro effects of interleukin-1 and tumor necrosis factor on murine cytomegalovirus infection. Biotherapy (Dordrecht, Netherlands), 1989, 1, 227-231.	0.7	15

#	Article	IF	Citations
595	The place of quinolones in the treatment of respiratory tract infections. Pharmaceutisch Weekblad, 1989, 11, 132-133.	0.7	0
596	Statistical analysis of fever interval data. European Journal of Clinical Investigation, 1989, 19, 154-158.	3.4	8
597	Comparison of the effects of recombinant interleukin 6 and recombinant interleukin 1 on nonspecific resistance to infection. European Journal of Immunology, 1989, 19, 413-416.	2.9	68
598	Differences in the synthesis and kinetics of release of interleukin 1Î±, interleukin 1Î² and tumor necrosis factor from human mononuclear cells. European Journal of Immunology, 1989, 19, 1531-1536.	2.9	152
599	In vitro production of IL 1Î², IL 1Î±, TNF and IL 2 in healthy subjects: distribution, effect of cyclooxygenase inhibition and evidence of independent gene regulation. European Journal of Immunology, 1989, 19, 2327-2333.	2.9	183
600	Clinical and immunological studies in patients with an increased serum IgD level. Journal of Clinical Immunology, 1989, 9, 393-400.	3.8	25
601	The Effect of Dietary Supplementation with nâ€”3 Polyunsaturated Fatty Acids on the Synthesis of Interleukin-1 and Tumor Necrosis Factor by Mononuclear Cells. New England Journal of Medicine, 1989, 320, 265-271.	27.0	1,843
602	Induction of circulating tumor necrosis factor (TNFÎ±) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients. Journal of Clinical Immunology, 1988, 8, 426-436.	3.8	201
603	Non-radioactive in situ hybridization for the detection of cytomegalovirus infections. Histochemistry, 1988, 88, 367-373.	1.9	25
604	The influence of culture conditions and serum lipids on interleukin-1 production by human monocytes. Journal of Immunological Methods, 1988, 108, 19-26.	1.4	12
605	Measurement of immunoreactive interleukin-1Î² from human mononuclear cells: Optimization of recovery, intrasubject consistency, and comparison with interleukin-1Î± and tumor necrosis factor. Clinical Immunology and Immunopathology, 1988, 49, 424-438.	2.0	172
606	Induction by Toxic-Shock-Syndrome Toxin-1 of a Circulating Tumor Necrosis Factor-Like Substance in Rabbits and of Immunoreactive Tumor Necrosis Factor and Interleukin-1 from Human Mononuclear Cells. Journal of Infectious Diseases, 1988, 158, 1017-1025.	4.0	117
607	Meningococcal pericarditis in the absence of meningitis. Infection, 1987, 15, 109-110.	4.7	8
608	Cell surface characteristics and DNA content of macrophages in murine bone marrow cultures. Histochemistry, 1987, 86, 433-436.	1.9	3
609	Interleukin-1 in the pathogenesis of fever. European Journal of Clinical Investigation, 1987, 17, 469-474.	3.4	42
610	Selective Antimicrobial Modulation of the Intestinal Microbial Flora for Infection Prevention in Patients with Hematologic Malignancies: Evaluation of Clinical Efficacy and the Value of Surveillance Cultures. Scandinavian Journal of Infectious Diseases, 1986, 18, 153-160.	1.5	26
611	Campylobacter jejuni bacteraemia as a cause of recurrent fever in a patient with hypogammaglobulinaemia. Journal of Infection, 1986, 12, 235-239.	3.3	29
612	Restriction of Longâ€term Indwelling Urethral Catheterisation in the Elderly. British Journal of Urology, 1986, 58, 683-688.	0.1	48

#	Article	IF	Citations
613	Is aciclovir prophylaxis necessary after bone marrow transplantation?. Infection, 1986, 14, 122-124.	4.7	6
614	Pharmacokinetics of vibunazole (BAY n 7133) administered orally to healthy subjects. Journal of Antimicrobial Chemotherapy, 1985, 16, 75-79.	3.0	6
615	Present Status of the Management of Patients with Defective Phagocyte Function. Clinical Infectious Diseases, 1984, 6, 107-121.	5.8	17
616	Branhamella catarrhalis septicaemia in a granulocytopenic patient. Infection, 1984, 12, 208-209.	4.7	12
617	Limited value of acyclovir in the treatment of uncomplicated herpes zoster: A placebo-controlled study. Infection, 1984, 12, 338-341.	4.7	26
618	Selective Antimicrobial Modulation of the Intestinal Flora of Patients with Acute Nonlymphocytic Leukemia: A Double-Blind, Placebo-Controlled Study. Journal of Infectious Diseases, 1983, 147, 615-623.	4.0	116
619	Acyclovir in severe herpes virus infections. American Journal of Medicine, 1982, 73, 271-274.	1.5	22
620	Binding and degradation of soluble immunoglobulin aggregates by mouse mononuclear phagocytesâ€"Stimulation by colony-stimulating factor. Cellular Immunology, 1982, 73, 98-105.	3.0	4
621	Hematogenous candida vertebral osteomyelitis treated with ketoconazole. Infection, 1982, 10, 290-292.	4.7	26
622	Bacterial arthritis caused by mycobacterium terrae. Infection, 1981, 9, 204-207.	4.7	10
623	Selective Antimicrobial Modulation of Human Microbial Flora: Infection Prevention in Patients with Decreased Host Defense Mechanisms by Selective Elimination of Potentially Pathogenic Bacteria. Journal of Infectious Diseases, 1981, 143, 644-654.	4.0	155
624	CSF concentrations of ketoconazole. Journal of Antimicrobial Chemotherapy, 1980, 6, 681-681.	3.0	15
625	The influence of gastric acidity on the bio-availability of ketoconazole. Journal of Antimicrobial Chemotherapy, 1980, 6, 552-554.	3.0	150
626	Prolonged bleeding time during azlocillin therapy. Journal of Antimicrobial Chemotherapy, 1980, 6, 554-556.	3.0	6
627	Infectious episodes in severely granulocytopenic patients. Infection, 1979, 7, 171-175.	4.7	23
628	Suspension cultures of mononuclear phagocytes in the Teflon culture bag. Cellular Immunology, 1979, 42, 208-212.	3.0	56